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ABSTRACT
INTRODUCTION: Abnormalities of energy expenditure (EE) in obesity and
type II diabetes mellitus have been described in animal models and adult
man and it has been suggested that these abnormalities predispose to weight
gain. In rodents there is evidence for a requirement for insulin in regulatory
thermogenesis mediated via brown adipose tissue (BAT).
The hypotheses that, firstly, insulin has a role in the control of EE and,
secondly, that this is mediated by BAT in adult man were tested in the
present studies.
METHODS: Three components of daily EE;resting metabolic rate (RMR), and
the thermic responses to a mixed liquid meal (32.6 K3/kg) and to an infusion
of noradrenaline (NA), 0.1 yg/kg/min, were measured using indirect
calorimetry in type I and type II diabetic subjects.
The components of EE were measured in 9 lean type I diabetics initially
while poorly controlled on conventional therapy (CT), HbAi 12.1±0.7%;
(mean±SEM), and then when optimally controlled on continuous subcutaneous
insulin infusion (CSII) (HbA[ 7.5±0.2%). The response to fat supplementation
for one week (5.23 M3/day) was assessed and the results compared to 8
non-diabetic control subjects.
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These parameters were also measured in 8 type II diabetics controlled on
diet and oral hypoglycaemic agents (HbA[ 8.6±0.7%) in order to ascertain
whether the alterations in body weight during metformin therapy (weight
loss) or sulphonylurea therapy (weight gain) were reflected in alterations of
EE.
An estimation of the thermogenic potential of BAT in adult man was
attempted by histological (light and electron microscopy) and biochemical
(GDP binding, cytochrome c oxidase activity and respiration of isolated
mitochrondia and adipocytes) studies on perirenal BAT obtained at post
mortem and during surgery.
RESULT5:
1. Poorly controlled type I diabetic subjects had a significantly (p<.01)
raised RMR (4.92±0.27 KJ/min) which returned to predicted value
(4.6±0.34 K3/min) on attainment of optimal glycaemic control. This
decrease in RMR may partly explain the mean gain in weight (3.5 kg)
observed during CSII. The thermic response to infused NA was decreased
by over 50% during CT (27.1 ±3.^ K3 controls vs. 11.1 ±3.7 K3 diabetic
CT; p<.01) and did not significantly improve during CSII (13.4±3.7 KJ).
A blunted thermic response to a meal was observed during fat
supplementation with CT (44.8± 14.0 KJ) but CSII corrected this (71 ±9.9
KJ). Hence insulin has a role in the control of EE but precise
replacement does not correct all these abnormalities in Type I diabetes
mellitus.
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2. Type II diabetic subjects had a normal RMR and thermic responses and
these were similar whether on metformin or sulphonylurea therapy. This
suggests that alterations in EE do not account for the changes in weight
during treatment with these agents.
3. Histological and biochemical studies demonstrated the presence of
functional BAT in adult man with activity equivalent to the partially
cold-adapted guinea pig suggesting some potential for thermogenesis in
adult man. However, it was calculated that this tissue can account for
only 0.2% of the rise in oxygen consumption during NA infusion and
suggests that this tissue has little energetic significance in adult man.
CONCLUSIONS: These data suggest that although type I diabetes mejlitus
may be associated with abnormalities of EE these are unlikely to be
mediated through BAT metabolism in man.
PREFACE
"You will see one man fat who eats moderately well and another lean
who eats a great deal".
- James Boswell, 1782
This apparent paradox observed by that irascible Scot, James Boswell,
remains as hotly debated a topic amongst the lay and scientific population
in the present day as it did over two hundred years ago.
Obesity is now a major public health problem in the Western world
and can be considered a multisystem disorder responsible for an excess of
mortality and morbidity in over one-fifth of the adult population. Apart
from the association of obesity with type II diabetes mellitus and
cardiovascular disease; gallbladder disease, an excess of carcinomas of the
large bowel and prostate, osteoarthritis and respiratory problems are well
recognised complications of this disorder (Royal College of Physicians,
1983).
Yet, although it is universally agreed that obesity must result from an
imbalance between energy intake and expenditure, there is still no clear
understanding of the influence of each of these parameters in the aetiology
of obesity in man. Studies which have attempted to examine the role of
energy intake have failed to demonstrate a conclusive link between
hyperphagia and obesity (Garrow, 1978). One major epidemiological survey
involving over 3,^00 subjects reported the unexpected finding of negative
correlations between energy intake and obesity and energy intake and
glucose intolerance (Keen et. al., 1979). Methodological problems may
partly explain these paradoxical results as one of the major obstacles to the
accurate measurement of nutrient intake has been that the caloric intake of
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free-living subjects, under the influence of the social and environmental
factors that dictate what type and how much food we eat, is probably very
different from intakes recorded under the different pressures of taking part
in a scientific dietary survey. A recent report has suggested that errors in
assessment of dietary intake may approach 500 kcal/day (Prentice et. al.,
1986).
However, the alternative explanation for these findings, which has
increasingly been investigated recently, is that a diminution of energy
expenditure may contribute to the development of obesity. This school of
thought is supported by evidence from animal models in which dissipation of
excess energy through brown adipose tissue metabolism results in the
maintenance of body weight during dietary excess (Rothwell and Stock,
1979) and conversely abnormalities of this tissue appear to predispose to
weight gain in certain genetically obese strains of mice (Trayhurn et.
al., 1977).
Abnormalities of thermogenesis have been demonstrated in some
obese subjects (Jung et. al., 1979; Shetty et. al., 1981) and it has been
suggested that these abnormalities may predispose to the obese state by
limiting energy expenditure in man (James and Trayhurn, 1981).
More recently, insulin resistance has been demonstrated to limit
energy expenditure following intravenous (Ravussin et. al., 1985) and oral
glucose (Golay et. al., 1982) in obese and type II diabetic subjects and it has
been further suggested that insulin may have a key role in controlling
energy expenditure in man (Felig, 1984).
Animal research has supported this concept as insulin appears to have
a permissive role in the expression of brown adipose tissue thermogenesis
(Seydoux et. al., 1983) and the ability to increase energy expenditure in
response to overfeeding is diminished when rats are rendered diabetic and is
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corrected by insulin replacement ( Rothwell and Stock, 1981).
Thus considerable evidence has accumulated implicating insulin in the
control of energy balance and the aims of the present studies were to
examine further aspects of energy expenditure in diabetic and non-diabetic
man.
In Chapter I, the evidence for the thermogenic hypothesis and its
application to animal models of obesity and lean, obese and diabetic man
will be reviewed.
Following a description of the methodology, results of experiments
designed to examine the role of insulin in modulating energy balance
outwith the context of obesity will be presented by studying the effect of
glycaemic control on energy expenditure in lean type I diabetic subjects.
Weight control is a major problem in the management of the type II
diabetic subject on oral glycaemic therapy. Experiments were therefore
designed to determine whether the documented weight loss on metformin
therapy and the tendency to gain weight on sulphonylurea derivatives
(Clarke and Duncan, 1968) are related to alterations of energy expenditure
in these subjects.
The thermogenic hypothesis of obesity in animals and its extrapolation
to adult man hinges on the central role of brown adipose tissue in the
control of energy expenditure. In the recommendations of the Royal College
of Physicians Report on Obesity (1983) it was noted
"no hormonal basis for the metabolic susceptibility to weight gain has
yet been found. More work is needed before possible mechanisms . . .
e.g., brown adipose tissue metabolism can be defined and shown to be
quantitatively important in determining weight gain"
- (Recommendation No. 6).
The final aim of the present studies was to attempt to determine the






Obesity is a major clinical problem and it is well documented that a
proportion of obese subjects develop clinical diabetes and that many diabetic
subjects are overweight.
Animal studies have indicated the importance of thermogenesis in the
maintenance of a stable weight during overfeeding and that abnormalities of
this homeostatic mechanism may result in obesity. In small rodents
regulatory thermogenesis is mediated via brown adipose tissue metabolism
and evidence suggests that insulin may have a role in the hormonal control
of the activity of this tissue.
Some, but not all, studies in obese and type II diabetic man have also
demonstrated abnormalities of thermogenesis and it has been suggested that
these abnormalities may predispose to the development of obesity by
limiting energy expenditure. It has also been suggested that glucose
intolerance and/or frank diabetes may further exacerbate this limitation of
energy expenditure. The principal site of regulatory thermogenesis in man
has, by extrapolation, been presumed to reside in brown adipose tissue;
however there is little evidence to confirm or refute this hypothesis.
This introductory chapter summarises the results of studies performed
in animals and man which have addressed the thermogenic hypothesis of
obesity and provides the background to the aims of the present studies which
were to examine further the role of glucose tolerance in the control of
energy expenditure in lean non-diabetic and type I and type II diabetic man




The thermogenic hypothesis dates back to the beginning of this
century when the German physiologist, Neumann (1902), coined the term
"lukuskonsumption" (literally, energy consumption) in an attempt to account
for the relative constancy of his own body weight despite fluctuations in
energy intake of over 30% during a three year period. The hypothesis
postulates the existence of a homeostatic mechanism in man responsible for
the maintenance of a stable body weight despite alterations in energy
intake. Thus, when food is available ad libitum energetically wasteful (or
thermogenic) mechanisms would be initiated to dissipate excess calories and
prevent weight gain; conversely during periods of limited food availability
these mechanisms would be inhibited to promote storage of energy. An
extension of this argument would predict that subjects in whom this complex
physiological system was disturbed, would demonstrate abnormalities of
energy expenditure which could predispose to weight gain.
Before discussing the evidence for the existence of such a mechanism
in animal models and man it is necessary to describe the various components
that contribute to total daily energy expenditure in man.
1.2. COMPONENTS OF ENERGY EXPENDITURE
Energy expenditure is measured as the heat generated by the body
either directly by the measurement of heat loss or indirectly by the
calculation of heat production resulting from substrate oxidation.
To study the role of energy output in the regulation of body weight it
is useful to divide daily energy expenditure into three separate components





























Fig. 1.1. Energy Expenditure and Thermogenesis
(a) Components of energy expenditure
(b) Components of thermogenesis
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1.2.1. Basal Metabolic Rate (Definition : Section 2.1.3)
Basal metabolic rate accounts for approximately 70% of total daily
energy expenditure and is related to age, sex, fat free mass and thyroid
status of the individual (Jequier, 1984). It represents the sum of energy
expended to maintain mechanical processes such as resting muscle tone and
myocardial contraction; osmotic pumps and the synthesis and breakdown of
the major substrates - protein, carbohydrate and fat.
1.2.2. Thermogenesis (Fig. 1.1 .(b))
Thermogenesis is defined as the energy expenditure above the basal
metabolic rate in the resting state and includes the effects of food intake,
cold exposure, stress and thermogenic agents such as caffeine (Jung et. al.,
1981), ephedrine (Astrup et. al., 1985(a)) and cigarette smoking (Hofstetter
et. al., 1986).
1.2.2.1. Diet induced thermogenesis
Among the factors that stimulate thermogenesis in man, food intake
plays a major role. Many expressions have been used to describe this
phenomenon including specific dynamic action (SDA), postprandial thermo¬
genesis and diet induced thermogenesis; the latter being the most widely
employed nowadays. Diet induced thermogenesis consists of two components.
The major component is the energy cost of digestion, absorption and storage
of ingested nutrients - these processes are known collectively as
"obligatory thermogenesis". However, for example, when glucose is infused
the observed glucose induced thermogenesis is in excess of the calculated
energy cost of absorption, oxidation and glycogen and lipid synthesis
(Thiebaud et. al., 1983). This component of diet induced thermogenesis which
cannot be accounted for by obligatory thermogenesis has been called
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"facultative thermogenesis" (Acheson et. al., 1984). In small mammals
there is considerable evidence that this latter component is expressed via
brown adipose tissue (BAT) under the control of the sympathetic nervous
system (Landsberg and Young, 1983).
In man there is evidence of sympathetic mediation of facultative
thermogenesis as glucose induced thermogenesis can be partially suppressed
with B-blockade (Acheson et. al., 1984). It is this component of diet induced
thermogenesis that has been speculated to have a role in the adaptive
response to overfeeding in man (Jequier, 1984).
1.2.2.2. Cold induced thermogenesis
The metabolic response to cold exposure consists of two components:
shivering thermogenesis which occurs as a consequence of muscular
contraction and non-shivering thermogenesis which results from biochemical
reactions not coupled to muscular activity.
Non-shivering thermogenesis in rats is largely attributable to brown
adipose tissue activity and can be mimicked by injection of noradrenaline
(Foster and Frydman, 1978(a)).
Human subjects also demonstrate non-shivering thermogenesis which is
easily demonstrable in the neonate (Hey, 1975).
In the adult, cold exposure during curarisation, which inhibits muscular
contraction, results in an increase in oxygen consumption (Jessen et. al.,
1980) and noradrenaline infusion results in similar increases in energy
expenditure (dung et. al., 1979; Joy, 1963). Noradrenaline infusion has thus




In most adults physical activity accounts for up to 20% of total daily
expenditure (Fig. 1.1(a)). The energy cost of daily activity is difficult to
assess and varies considerably both between individuals and in the same
individual over a period of time. There is no evidence, as yet, to suggest that
some feature of this component predisposes to the obese state although it
remains a major adjunct to therapy in the management of the overweight
subject.
1.3. THERMOGENESIS IN SMALL MAMMALS
1.3.1. Non-shivering Thermogenesis
Over 50 years following Neumann's original concept of
"luxuskonsumption" (Neumann, 1902) the first preliminary evidence for
abnormalities of energy expenditure predisposing to the development of the
obese state was presented by Davis and Meyer (1954) who demonstrated
defective thermoregulation in the genetically obese (ob/ob) mouse. They
observed that these obese mutants died rapidly of hypothermia when exposed
to an ambient temperature of 4°C in contrast to the survival of their lean
littermates. This work was later confirmed and extended by Trayhurn and
colleagues who demonstrated a diminished ability of the ob/ob mouse to
initiate non-shivering thermogenesis both at low environmental temperature
and in response to noradrenaline (Trayhurn and 3ames, 1978). Further, this
reduction in energy expenditure occurred prior to the development of
hyperphagia in these animals (Trayhurn et. al., 1977) and could result in




During this period the contribution of BAT to the metabolic response
to cold and noradrenaline in the newborn mammal such as the lamb
(Alexander et. al., 1973), rabbit (Dawkins and Hull, 1964) and the human
neonate (Aherne and Hull, 1966) was well recognised but its role in
thermogenesis in the adult mammal was less well established. The relatively
small amount of BAT present in the adult mammal (less than 1-2% body
weight) and blood flow studies performed at this time suggested that this
tissue did not have a major role in adult thermogenesis (Jansky and Hart,
1968).
Three major mechanisms to account for the cellular dissipation of heat
through wasteful hydrolysis of ATP had been proposed.
The most clearly established mechanism was shivering itself in which
ATP is utilised to provide energy for the random contractions of the
acto-myosin complex (Fig. 1.2(a)) but obviously this cannot account for the
non-shivering mechanisms.
Substrate cycling (Newsholme and Crabtree, 1976) occurs when two
intermediates can be interconverted by two independent pathways one of
which requires ATP which is not replenished in the reverse reaction. A classic
example of this is the interconversion of fructose-6-phosphate to fructose-1,
6-bisphosphate in the glycolytic sequence (Fig. 1.2(b)) which contributes to
the maintenance of thorax temperature in the flight muscle of the Bombus
bumble bee. The triglyceride fatty acid cycle (Fig. 1.2(c)) is a similarly
wasteful cycle but has recently been calculated to account for the
dissipation of less than 10 kcal/day in man (Hammond and Johnston, 1987).
The final type of ATP hydrolytic mechanism which has been proposed
relies upon Na-cycling at the plasma membrane and subsequent hydrolysis of
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ATP by Na+-K+' ATPase. Although this mechanism may contribute towards
thyroid induced thermogenesis (Smith and Edelman, 1979) evidence for this
as a major thermogenic mechanism is lacking (Nicholls and Locke, 1983).
The major breakthrough in our understanding of mammalian
thermogenesis occurred when Foster and Frydman (1978a) demonstrated that
non-shivering thermogenesis in adult rats, as in younger animals, was in fact
due primarily to BAT. Using a radiolabeled microsphere technique to
calculate blood flow to different organs they showed that cold adapted rats
infused with noradrenaline had an increase in blood flow to brown adipose
tissue of about 31% of the cardiac output, while the increased flow to
skeletal muscle was only in the region of 5% of the cardiac output. They
calculated from arteriovenous oxygen uptake across interscapular brown
adipose tissue that this tissue accounted for at least 60% of the calorigenic
response of the cold adapted rat to infused noradrenaline, while skeletal
muscle could not have been responsible for more than 12% of the increased
heat production. They also demonstrated that the previous estimates of
86 +
blood flow to BAT using Rb were erroneous as this technique overestimates
when blood flow rates are low and underestimates when high (Foster and
Frydman, 1978b).
Thus, the major effector of non-shivering thermogenesis in small
mammals appeared to be the relatively small tissue mass of BAT.
1.3.2. Diet Induced Thermogenesis
In 1979 Rothwell and Stock made the important observation that adult
rats could become effectively cold-adapted simply by overfeeding. They
performed a series of experiments in which normal rats were offered various
palatable food items such as chocolates and crisps in addition to the normal
stock diet. This "cafeteria feeding", as it became known, resulted in an
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increase in energy intake of 80% yet the small weight gain that occurred
accounted for only 8% of the excess energy consumed (Rothwell and Stock,
1979). A significant proportion of the remainder had been dissipated as heat
as demonstrated by a 30% increase in resting oxygen consumption. The
increase in thermogenesis could be abolished by propranolol indicating
beta(8)-mediated sympathetic activation. The cafeteria rats also demonstrated
a 70% increase in oxygen consumption in response to the injection of
noradrenaline compared to 6% in controls and this was associated with
hyperplasia of brown adipose tissue.
1.3.3. The Cellular Mechanism of Brown Adipose Tissue Metabolism
1.3.3.1. Anatomy
In mammals brown adipose tissue is located in relatively small
deposits in a number of sites, in particular, in the interscapular region and
along the great vessels of the thorax and abdomen (Dawkins and Hull, 1965).
The structure and function of brown adipose tissue differs markedly from
those of white adipose tissue. Each brown adipocyte possesses multilocular
fat droplets in association with numerous mitochondria with dense cristae
(Nedergaard and Lindberg, 1982). In contrast, the storage role of the white
adipocyte is facilitated by a large unilocular fat droplet and its relative
metabolic inactivity is reflected in a paucity of mitochondria.
Brown adipose tissue has an extensive capillary vascular network and
its metabolism is regulated by rich sympathetic innervation (Girardier, 1983)
in response to the major stimuli that promote thermogenesis - cold and food
ingestion. The subsequent 8-adrenergic stimulation initiates cyclic-AMP
dependent activation of triglyceride lipase. The resultant fate of released




distant organs as in white adipose tissue, but to act as a messenger to
uncouple oxidative phosphorylation.
1.3.3.2. Uncoupled oxidative phosphorylation
The uncoupling hypothesis of brown adipose tissue thermogenesis was
proposed by Nicholls (1976) and is schematically represented in Fig. 1.3.
According to the chemiosmotic theory of mitochondrial substrate oxidative
phosphorylation the flow of protons from the matrix across the inner
mitochondrial membrane and their reentry back across this membrane is
linked to the generation of ATP from ADP (Fig. 1.3, Step 5). Nicholls
demonstrated the existence of a secondary pathway in brown adipose tissue
mitochondria which facilitated the return of protons independent of ATP
synthesis thus allowing substrate oxidation without ATP production (Nicholls
and Locke, 1983).
This proton conductance pathway, which appears to be unique to brown
adipose tissue mitochondria, is inhibited by purine nucleotides in particular
guanosine diphosphate (GDP) and adenosine diphosphate (ADP). The
nucleotides bind to a specific 32,000 Dalton protein located on the inner
mitochondrial membrane. The competitive binding of long chain fatty acyl
CoA molecules displace the purine nucleotides and allows the leakage of
protons uncoupled to ATP synthesis.
The acute sequence of events would be as follows: noradrenaline
interacts with the B-receptor on the plasma membrane activating adenyl
cyclase and cyclic AMP production (Fig. 1.3, Step 1). Activation of
triglyceride lipase results in the production of non-esterified fatty acids and
acyl CoA (Fig. 1.3, Step 2). Acyl CoA then displaces purine nucleotides at
the inner mitochondrial membrane (Fig. 1.3, Step 3) thus resulting in
functional uncoupling and the production of heat from fatty acid oxidation
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without ATP synthesis (Fig. 1.3, Step 4).
1.3.3.3. Control of Brown Adipose Tissue Metabolism
Chronic adaptation to cold and overfeeding is reflected in the
concentration of the 32,000 Dalton protein, thus the increased thermogenic
capacity of this state is associated with hyperplasia of BAT, increase in the
mitochondrial number (Buckowiecki et. al., 1982) and the concentration of
the 32,000 Dalton protein in the inner mitochondrial membrane (Desautels
et. al., 1978; Brooks et. al., 1980). This process appears to be under the
control of the ambient sympathetic tone as this trophic response can be
almost entirely abolished by pharmacological sympathectomy (Mory et. al.,
1982) and mimicked by the presence of the catecholamine secreting tumour
phaeochromocytoma (Ricquier et. al., 1983) and chronic noradrenaline
infusion (Mory et. al., 1984). Thyroid, pituitary and adrenocortical hormones
appear to have only a permissive effect (Himms-Hagen, 1984).
1.3.3.4. Insulin and Brown Adipose Tissue Metabolism
Abnormalities of both non-shivering and diet-induced thermogenesis
have been reported in association with animal models of diabetes mellitus.
Rothwell and Stock (1981) demonstrated that rats rendered diabetic
following the administration of streptozotocin failed to exhibit diet induced
thermogenesis in response to cafeteria feeding and had blunted responses to
the injection of noradrenaline both on normal stock-fed diet as well as
during cafeteria feeding. Insulin replacement restored these responses to
normal. They also demonstrated the failure of diabetic rats to maintain body
temperature when exposed to cold (5°C) and confirmed the findings of Drury
(1957) that these rats cannot survive cold environments unless replaced with
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insulin.
Seydoux et. al., (1983) studied interscapular brown adipose tissue from
streptozotocin diabetic rats and demonstrated atrophy of the fat pad, a
diminished DNA and protein content, diminished basal and noradrenaline
stimulated heat production and a reduced capacity for fatty acid oxidation.
This group (Seydoux et. al., 1984) also demonstrated that indices of the
thermogenic state (GDP binding and 32,000-MR protein) were decreased in
streptozotocin diabetic rats and markedly increased following chronic
infusion of insulin. Further evidence of the involvement of insulin in the
genesis of energy dissipation in response to overfeeding was provided by
Cunningham et. al., (1983). They made the important observation that in rats
who became glucose intolerant during cafeteria feeding efficiency of weight
gain was 18% higher than those rats with normal glucose tolerance. This was
correlated with a failure of brown adipose tissue to increase in cellularity in
response to cafeteria feeding and from these data they hypothesised that
the link between diabetes and obesity may be bidirectional: obesity
increasing the risk of development of diabetes, and impaired glucose
tolerance accelerating the development of obesity by enhancing efficiency
of weight gain.
Genetic models of obesity such as the ob/ob and db/db mouse also
demonstrate abnormalities of thermogenesis in association with impaired
glucose tolerance (Trayhurn and Fuller, 1980) and these factors may further
compromise the already predisposed animal.
1.3.3.5. Summary - Brown Adipose Tissue Metabolism in Small Rodents
From this understanding of BAT physiology, cold and diet induced
thermogenesis in normal rodents and the abnormalities of this process in the
obese (ob/ob) mouse can now be explained in terms of brown adipose tissue
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metabolism.
Sympathetic stimulation in the normal rat in response to cold or food
results acutely in the uncoupling of mitochondrial oxidative phosphorylation
and energy dissipation in the form of heat. The chronic adaptive response to
cold or overfeeding results in the synthesis of uncoupling protein thus
increasing the thermogenic potential of BAT.
Low concentrations of uncoupling protein (measured by the binding of
radiolabeled GDP) account for the inability of the ob/ob mouse to increase
heat production in response to sympathetic stimulation and burn off the
excess energy consumed and thus it tends to gain weight (Brooks et. al.,
1980).
1.4. THERMOGENESIS IN ADULT MAN
From these animal models, research in the field of control of energy
balance and obesity in man became focussed in two areas.
Firstly the identification of a regulatory mechanism which could
"buffer" weight gain during overfeeding and secondly the presence or
absence of abnormalities of sympathetic or diet induced thermogenesis in
obese subjects.
1.4.1. Evidence from experimental overfeeding
Anecdotal evidence for the presence of a homeostatic mechanism
which would maintain body weight despite fluctuations in energy intake
abounds in non-scientific and early scientific literature alike (Neumann,
1902; Gulick, 1922). However, it was not until the 1960s that experimental
overfeeding confirmed this observation by demonstrating that a significant
proportion of the excess energy intake could not be accounted for by the
subsequent weight gain (Miller and Mumford, 1967; Durnin and Norgan,
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1969). In one of the longest term overfeeding studies performed in the
Vermont prisoners some individuals who normally maintained their weight on
12.6 MJ/day (3000 kcals), after several months of overfeeding required 23.8
MJ/day (5700 kcals) to maintain only slightly heavier weights (Sims, 1976).
This increase in energy consumption was at least 40% in excess of the
requirement to maintain the rise in RMR due to increased body weight and
demonstrates that appreciable changes in food intake can be tolerated with
only small changes in body weight (Himms-Hagan, 1984).
Thus, although some studies have failed to find any increase in energy
expenditure during overfeeding (Glick et. al., 1977) the consensus of the
literature points to an energy dissipative process occurring during
overfeeding in man which some have construed as being analogous to the
adaptive thermogenesis observed by Rothwell and Stock (1979) in the
cafeteria fed rat (James and Trayhurn, 1981).
1.4.2. Evidence of altered thermogenesis in obese states in man
As there is no evidence for a decrease in the RMR predisposing obese
individuals to weight gain (Ravussin et. al., 1982; Felig et. al., 1983; Welle
et. al., 1984) attention has been focussed on those stimuli that increase
energy expenditure above basal - the thermogenic stimuli of exercise, food,
temperature and stress - in an attempt to identify whether differences in
these parameters can account for a tendency to weight gain in obesity.
Studies of the effects of exercise and stress in lean and obese
individuals are notoriousy difficult to perform reproducibly and thus to
interpret (Garrow, 1978) and will not be discussed further, although the
sympathetic component of these processes has been studied using noradrenaline
infusion as a pharmacological model.
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Cold adaptation has been studied by examining the thermic responses
not only to low environmental temperature but also to infused noradrenaline
as a measure of non-shivering thermogenesis analogous to that in animal
models.
Diet induced thermogenesis has been measured either as the thermic
response to individual nutrients such as carbohydrate, fat and protein or as
the thermic response to a meal.
1.4.2.1. Non-shivering thermogenesis
It is now generally accepted that non-shivering thermogenesis is an
important homeostatic mechanism in neonates to maintain body temperature
(Hey, 1975) and contributes to the increase in heat production in adult man
during acute cold exposure (Dauncey, 1981).
There is also evidence of an adaptive response in non-shivering
thermogenesis during prolonged cold exposure, which has been measured as
an enhancement of the thermic effect of infused noradrenaline (Joy, 1963;
Itoh, 1975). Differences in cold induced thermogenesis between lean and
obese subjects have been reported (Blaza and Garrow, 1983), which have
suggested that those with a propensity for obesity have a reduced drive for
non-shivering thermogenesis similar to that in genetically obese rodents.
Using noradrenaline as a measure of non-shivering thermogenesis,
blunted thermic responses to infusion of this catecholamine have been
demonstrated in obese and post obese subjects suggesting that this defect
was an inherent abnormality associated with the obese state (Jung et. al.,
1979). However, other groups have failed to demonstrate such an abnormality
in obese subjects (Katzeff et. al., 1986, Finer et. al., 1985).
Table 1.1 (overleaf)
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1.4.2.2. Diet induced thermogenesis
A similar division of opinion has appeared in the literature regarding
diet induced thermogenesis in lean and obese subjects. A summary of the
results of 15 studies that have examined this parameter is shown in Table
1.1. These conflicting findings may be partly explained by differences in the
caloric value of the meal, the length of time of study after ingestion, the
selection of controls, and the heterogeneity of the obese population.
1.4.3. Thermogenesis in diabetic man
Historically, the measurement of oxygen consumption in diabetic
subjects is not new.
Allen and Dubois (1916) studying the effect of starvation and an
oatmeal diet on Type I diabetes, disputed Benedict and Joslin's (1910)
previous findings of a 15-20% elevation of oxygen consumption and
-concluded that "the increase in basal metabolism in diabetes is generally
absent or slight".
Interestingly, Allen and Dubois also studied the specific dynamic
action of meals consisting of "97 g olive oil" or "125 mg oatmeal and 15 g
butter" and observed no difference "as respects promptness and intensity"
between diabetic and non diabetic subjects. They were obviously aware,
although did not quote, Neumann's (1902) recent work and they comment
"there was no indication of an abnormally high metabolism (Luxuskonsumption)
on the excessive diet". It was not until almost 70 years later that Nair et al
(1984) once again examined the resting metabolic rate in ketotic type I
diabetic subjects and found it to be significantly elevated. Studies of
non-shivering and diet-induced thermogenesis in Type I diabetes mellitus
have however not been reported in the literature since the pre-insulin era.
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The association of Type II diabetes with obesity has resulted in recent
attention to the study of the thermogenesis in these subjects. However these
studies have almost wholly concentrated on the thermic effect of a glucose
load.
In contrast to those reports in obese subjects (Table 1.1) the thermic
response to oral (Golay et. al., 1982; Schutz et. al., 1984b; Nair et. al., 1986)
and intravenous (Ravussin et. al., 1983) glucose has been consistently
demonstrated to be suppressed in obese diabetic and glucose intolerant
subjects compared to lean subjects (Fig. 1.4). The study of Nair et. al. (1986)
is interesting in two respects. Firstly it reports an elevation of the resting
metabolic rate above predicted values not only in diabetic subjects but also
those with impaired glucose tolerance. Secondly, the effect of glucose
intolerance/diabetes on the blunting of the thermic response to glucose
appeared to be independent to that of obesity in that the obese subjects in
this study, with similar body weight had a normal thermic response to
glucose. The data of Golay et. al. (1982) suggests that the degree of glucose
intolerance may further impair the thermic response to oral glucose in that
those subjects with a diminished insulin response to glucose (Fig. 1.4(b),
O-Dg) had the smallest thermic response. Thus, some of the thermic
abnormalities noted in animal models and diabetes are paralleled in diabetic
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1.5. BROWN ADIPOSE TISSUE IN ADULT MAN
1.5.1. Anatomy
It is an interesting coincidence that in the same year that Neumann
published his observations on "luxuskonsumption" an anatomist named Hatai
(1902) made the observation of the similarity between the interscapular
hibernating gland of certain rodents and the embryonal fat pad of human
neonates. These findings remained confined to that of an esoteric piece of
comparative anatomy until the demonstration of a function for this tissue in
the human neonate as a site for non-shivering thermogenesis (Aherne and
Hull, 1966). The first systematic study of the distribution of brown adipose
tissue in the human at different age groups (Heaton, 1972) demonstrated a
%
wide distribution of brown adipose tissue in all areas of the body in the first
decade of life but this tended to diminish with increasing age with loss, in
particular, from peripherally situated sites such as the interscapular area.
However, the deeper sites such as those in association with the great vessels
(cervical, pericardial and perirenal) tended to retain their brown fat up to
the eighth decade.
Table 1.2 summarises all studies to date regarding the distribution of
brown adipose tissue in adult man. All studies used post mortem material
with the exception of Astrup et. al. (198*0 who identified thermographicaliy
interscapular areas of heat production in response to ephedrine and obtained
tissue at the maximal "hot spot" using a fine needle biopsy technique. The
pooled data from this table illustrates the perirenal site as the major site of
persistence of brown adipose tissue in adult man.
The positive identification of brown adipose tissue was based
histologically on multilocularity of the adipocytes except in the study of
Lean et. al. (1986) where a specific radio-immunoassay for uncoupling
Study
Method
No.ofBATp sitivesampl s(observed/total) AgeInterscapularCervical
Perirenal
HeatonCJM(1972) HassiJ(1979) Astrupet.al(1984) Astrupet.al(1985b) Tanumaet.al(1976) Leant.al(1986)
Postmortemhistology Postmortemhistology Biopsy/histology Postmortemhistology Postmortemhistology Postmortem *RIAforuncoupling protein





24/31 12/34 141/174 68/85 5/17£ 250/341 73%
Table1.2:Histologicalccurr ncefbrowadiposeissunman.
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protein was used. It is interesting to note that in this study the highest
proportion of positive samples was found in those from the axillary site
(64%) which may represent a caudal extension of the cervical brown adipose
tissue depot. When all these results are pooled the perirenal fat depot
appears to be the most abundant source of brown adipose tissue in man and
thus was chosen for the present study.
1.5.2. Evidence for Activation of Brown Adipose Tissue in Man
1.5.2.1. Phaeochromocytoma
Several case studies report the presence of highly vascular brown fat
tumours or "hibernomas" in association with catecholamine secreting
phaeochromocytoma tumours (Rona, 1964; Leiphart and Nudelman, 1970;
English et. al., 1973). The presence of uncoupling protein has also been
demonstrated in perirenal fat obtained from patients with phaeochromo¬
cytoma (Ricquier et. al., 1982; Bouillard et. al., 1983) and may be elevated
(Lean et. al., 1986) suggesting that activation of this tissue may occur in the
presence of high concentrations of circulating noradrenaline.
1.5.2.2. Thermography
As an addendum to their classic demonstration of diet induced
thermogenesis in cafeteria fed rats Rothwell and Stock (1979) showed
thermographically increased blood flow to the interscapular area in one
subject following the administration of an unspecified dose of ephedrine.
This was interpreted as evidence of interscapular brown adipose tissue
thermogenesis in man. These findings of increased blood flow in the
interscapular area following epherdine administration have been confirmed
by other workers (Lev-Bari 1982; Astrup et. al., 1984) but the latter group
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were unable to demonstrate the histological presence of brown adipose tissue
in these areas (Table 1.2).
1.5.2.3. Cold adaptation
Huttunen et. al., (1981) examined the incidence and enzymic activity
of brown adipose tissue in eleven outdoor and ten indoor workers at up to
five days post mortem and concluded from these measurements of
mitochondrial enzymes performed under variable conditions that there was
evidence of increased brown adipose tissue activity in subjects with increased
cold exposure. As the major adaptive response to cold in Western man
(especially in Finland) is to diminish heat loss by adding another layer of
insulation (i.e. clothing) it is unlikely that significant cold adaptation was
observed in these subjects.
1.5.3. Function of brown adipose tissue in man
To date, although there is ample evidence of the histological presence
of small amounts of brown adipose tissue persisting in adult man there is no
evidence to support a functional role for this tissue in adaptive thermogenesis.
The association of similar thermic abnormalities in animal models of obesity
and human obesity, the demonstration of a possible adaptive thermogenic
mechanism similar to the cafeteria feeding model in rats and finally the
anatomical demonstration of brown adipose tissue in man has led to the
speculation that this tissue may be responsible for adaptive thermogenesis in
man and, further, that abnormalities of this tissue may be involved in the
aetiology of obesity.
However, histological evidence of this tissue in adult man does not
necessarily infer function. The inaccessibility of this tissue in man
has rendered it particularly unamenable to study in vivo and therefore
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experiments were designed (Chapter V) to attempt to examine the functional
capacity of perirenal brown adipose tissue in man using indirect methods.
1.6. CONCLUSIONS
From the foregoing discussion it is apparent that several questions
remain unanswered regarding the control of energy expenditure in adult man
and thus the present studies were designed to attempt to clarify several
points.
Firstly, it is not clear from the literature what the effect of abnormal
glucose tolerance per se is on energy expenditure and thermogenesis in man
in that studies examining this problem have almost exclusively been
performed in subjects who are also obese. Therefore, I have measured several
components of energy expenditure in non-obese type I diabetic subjects
during a period of poor glycaemic control on conventional insulin therapy
(Chapter III).
Secondly, to demonstrate if abnormalities of energy expenditure in
these subjects are due to poor glycaemic control alone or to other metabolic
abnormalities associated with diabetes mellitus, the type I subjects have
been studied after a period of continuous subcutaneous insulin infusion to
observe whether improvements in glucose tolerance results in a reversal of
the thermic abnormalities (Chapter III).
Thirdly, in an attempt to identify whether thermogenic mechanisms
have a therapeutic role in the management of type II diabetes mellitus,
energy expenditure has been examined during biguanide therapy, which is
documented to promote weight loss, and during sulphonylurea therapy, which
tends to result in weight gain, in well controlled type II diabetic subjects
(Chapter IV).
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Finally, as the control of energy expenditure is firmly focussed on
brown adipose tissue in animals, yet evidence of its functional capacity in
man is lacking, I have attempted to assess the contribution of this tissue to





2.1. MEASUREMENT OF ENERGY EXPENDITURE IN MAN
2.1.1. Introduction
Calorimetry is the method of choice for studying energy expenditure
in man (Garrow, 1978). Several calorimetric methods are available to the
investigator based on the principles of either direct calorimetry which
measures heat dissipated from the body or indirect calorimetry which
measures heat production resulting from oxidative processes. , •
For the present study the requirements were that of a system capable
of measuring resting metabolic rate (RMR) and the short term changes (less
than three hours) resulting from oral and intravenous stimuli. The method
should also be sensitive to artefact, have a fast reaction time and be
comfortable and reproducible. The direct and whole body indirect calorimeters
using a respiration chamber are unsuitable for experiments of less than five
hours duration (Jequier, 1985) due to the slow equilibration time involved.
Indirect methods using a Douglas bag technique and mouthpieces involve a
certain amount of discomfort to the subject if the duration of the
experiment exceeds 20 minutes resulting in an artefactual rise in metabolic
rate (Garrow, 1978). A ventilated hood system was thus the method of choice
and had the additional advantages of being relatively inexpensive and easy
to maintain.
2.1.2. Indirect Ventilated Hood Calorimetry
RMR and the thermic responses to a test meal and intravenous
infusion of noradrenaline were measured using an indirect computerised
ventilated hood calorimeter based on an original system developed at the
Medical Research Council Dunn Nutrition Laboratory, Cambridge.
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Calibration of the oxygen and carbon dioxide meters was performed
at the beginning and end of each experiment with oxygen free nitrogen
(British Oxygen Corporation Ltd.), 0.8% carbon dioxide in air (British Oxygen
Corporation Ltd.) and room air. To ensure constancy of the room
environment during the experiments the calorimeter suite had a double door
entry system.
All measurements were performed under thermoneutral conditions
with subjects wearing light clothing and following a 10 hour overnight fast
and abstinence from caffeinated beverages and cigarette smoking.
Thermoneutrality is defined as that environmental temperature at which the
body temperature is maintained whilst heat production and evaporative
water loss are at a minimum (Hey, 1975). For the adult subject thermo¬
neutrality was taken as 26-28°C (Itoh, 1974).
2.1.3. Resting Metabolic Rate
Basal metabolic rate is defined as the energy output of an individual
under standardised conditions: bodily and mentally at rest 12-18 hours after
a meal in a thermoneutral environment (Garrow, 1978). As it is difficult in
practice to reproducibly achieve a total basal mental and physical state the
term RESTING METABOLIC RATE (RMR) is used throughout as it is a more
exact expression of that which is measured.
Measurements of RMR were performed between 0830 and 0930 hours
with subjects lying semi-recumbent following 30-45 minutes equilibration at
rest and after venous cannulation. Results are expressed as the mean ± SEM
of a 20 minute measurement.
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The principle of indirect calorimetry arose from the meticulous direct
calorimetric studies of Atwater and Benedict (1905), in which they observed
that heat production could be accurately predicted from measurements of
oxygen consumption and carbon dioxide production. Heat production was
calculated from the product of oxygen consumption (I/min) and the calorific
value of the oxygen determined from the respiratory quotient (RQ).
The ventilated hood system is illustrated in Figure 2.1. The
semi-recumbent subject rested on the bed with their head enclosed in a loose
fitting transparent hood through which room air was drawn at a constant rate
of 45 1/min. Expired air was withdrawn continuously for measurement of
oxygen (1/min) by paramagnetic analysis (Taylor, Servomex) and carbon
dioxide (1/min) by infra-red analysis (SS-200, Analytic Development
Company). Readings were taken at 1 minute intervals and the oxygen
consumption and carbon dioxide production were calculated as illustrated in
Table 2.1.
The standard formula of Weir (1949), based on a correction for the
non-protein respiratory quotient, was used to calculate heat production.
HEAT PRODUCTION (KJ/min) = 16.494 x 0^ consumption (1/min)
+ 4.62 x CO2 production (1/min)
Calculations were performed using a computer programme (Appendix 1)
Copyright Dunn Nutrition Laboratory, Cambridge) which allowed immediate
display of the parameters of O^ consumption (1/min), CO2 production (1/min),
RQ and heat production (KJ/min) on a visual display unit. This facilitated
the exclusion of artefactual results due to coughing, hyperventilation or
movement.
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Fig. 2.1 Ventilated hood calorimeter. Subject lying semirecumbent with
P.V.C. hood in position. Expired air is drawn from the hood to
the calorimeter which measures the concentration of expired
oxygen and carbon dioxide. Calculation of heat production is
facilitated by Commodore 8250 computer and results are
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Expired oxygen concentration %
Expired carbon dioxide concentration %
Expired nitrogen concentration % (100-ECO2"EO^)
V
STPD
Volume of expired air per minute at STPD
True Oxygen = EN., x RO, - EO
RN^
True Carbon Dioxide = ECO2-RCO2
(C02 production)
Respiratory Quotient = True CO^,
True O2
Oxygen Uptake = V<-Tpn x True Q? 1/min
(O2 consumption) 100
Table 2.1 - Calculation of True Oxygen, True Carbon Dioxide, Respiratory
Quotient and Oxygen Uptake.
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2.1.4. Ideal Body Weight
Ideal body weight (IBW) was defined as that given as an acceptable
average weight in the report of the Royal College of Physicians (1983) based
on the weight for height tables of the Metropolitan Life Insurance Company
(1960).
2.1.5. Thermic Responses
The thermic response to a meal or noradrenaline infusion is defined as
the rise in heat production (K3/min) above the resting value (RMR). Results
are expressed as the mean integrated rise during the period of study (KJ)
calculated from the area under the curve ± SEM.
2.1.5.1. Thermic response to a meal
A standard mixed liquid meal was administered following measurement
of the RMR and consisted of one sachet Carnation Build Up (Vanilla
Flavour), reconstituted in whole milk to give 32.6 KJ (7.8 Kcals)/kg ideal
.body weight. As subjects had the thermic responses to a meal measured on
several occasions the caloric load was calculated on an IBW basis rather than
total body weight to ensure a similar stimulus was given on each occasion.
The meal was designed to be similar in energy content and constituents to
that which diabetics would normally ingest each morning and had a
protein:fat:carbohydrate ratio of 1:1.2:2.3 and contained approximately 50 g
of carbohydrate. As most subjects will normally only tolerate about three
hours under the ventilated hood without discomfort or a desire to micturate
a liquid meal was chosen to facilitate the measurement of the thermic
response within that time. Metabolic rate was measured for two hours
continuously following replacement of the hood after meal ingestion and
measurement of RMR.
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Venous blood samples were obtained at -5, 0, 30, 60, 90 and 120
minutes following meal ingestion for analysis of plasma glucose.
2.1.5.2. Thermic response to noradrenaline infusion
An intravenous 21 gauge cannula (Abbot) was placed in the
contralateral brachial vein used for venous sampling. 0.9% normal saline
(Boots p.i.e.) was infused at the same rate of noradrenaline infusion during
the equilibration period and measurement of RMR.
Noradrenaline (Levophed, Winthrop), diluted in 0.9% saline was
infused at the rate if 0.1 yg/kg IBW/minute for 45 minutes and the metabolic
rate was measured continuously. The dose infused was chosen to result in a
plasma noradrenaline concentration corresponding to that found in moderate
exercise and previous work using a similar protocol achieved peak plasma
noradrenaline concentrations of 1 yg/L (dung, 1979). As with the meal the
dose was calculated per IBW to ensure reproducibility of experimental
conditions.
Venous blood for analysis of glucose, free fatty acid and glycerol
concentrations were withdrawn at -5, 0, +15, +30 and +45 minutes during
noradrenaline infusion.
2.1.6. Predicted Metabolic Rate
Predicted metabolic rate (K3/min) of each subject was calculated from
the DuBois normal standards modified by Boothby and Sandiford (1929)
based on the age, sex and surface area of the subject.
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2.2. BLOOD ASSAYS
2.2.1. Venous Blood Sampling and Collection
Venous blood samples were obtained using an indwelling 19 gauge
cannula (Abbot) placed in a brachial vein. A three-way tap was used to lock
the system; the cannula being kept patent with 0.5 ml 3.8% sodium citrate
(British Pharmacopoeia Codex) diluted 1 in 10 with 0.9% saline. Before any
blood samples were taken the cannula was emptied of sodium citrate by
withdrawing and discarding 2 ml of blood and citrate. Blood samples were
collected as follows:
1. Into EDTA tubes (Searle) for insulin and HbAj estimation.
2. Into fluorate oxalate tubes (Searle) for plasma glucose estimation.
3. Into glass tubes (Searle) for serum collection for glycerol, free
fatty acids and thyroxine, T3 and TSH estimations.
All tubes for plasma samples were cooled on ice, centrifuged at 2400
R.P.M. for 10 minutes and the plasma separated and frozen at -20°C until
assayed.
2.2.2. Plasma Glucose
Plasma glucose was assayed using an enzymatic colorimetric method
adapted from Trinder (1969) using a Technicon AAII glucose autoanalyser
system. In this method glucose and oxygen are converted to gluconic acid
and hydrogen peroxide by the enzyme glucose oxidase.
Glucose +C>2 + H^O ^ Gluconic acid +
Glucose Oxidase
The chromogen used was 4-aminophenazone which when added to
hydrogen peroxide in the presence of peroxidase results in the coloured
product Mp-benzoquinone-mono-imino)phenazone.
Absorbance of this compound was measured on a spectrophotometer at
520 nm. Standard curves were constructed for concentrations of glucose of 1,
2.5, 5, 7.5, 10, 15, 20 and 25 mmol/1 at the start and finish of each run. A
drift standard of 7.5 mnol/1 was included after every tenth unknown sample.
The inter-assay coefficient of variation (C.V.) was 3.2% and intra-assay C.V.,
2.0%.
2.2.3. Free Fatty Acids
Serum free-fatty acids (FFA) were measured using an extraction
photometric method adapted from Chromy et al. (1977). In this method 100
pi of serum is mixed with a stable aqueous copper reagent and a
chloroform-heptane- methanol (C-H-M) mixture. The copper ions in solution
react quantitatively with the FFA to form a complex (FFA-Cu soap) which is
extracted into the C-H-M upper phase.
Unreacted copper ions remain in the aqueous phase and an aliquot of
the C-H-M phase is mixed with a chromogenic reagent (l-(2-thiazolylazo)2-
naphthol (TAN)). The absorbance of the coloured product was measured at
570 nm. Standards were prepared from a 2 mmol/1 stock solution of sodium




palmitate in bovine albumin solution to give working solution concentrations
of 0.1, 0.25, 0.50, 1.0, 1.25 and 1.50 mmol/1. The intra-assay C.V. was 8.4%.
2.2.4. Glycerol
Serum glycerol was measured by a fully enzymatic method using a
BCL triglyceride kit (No. 125032) with lipases and esterases removed. In this
method glycerol is quantified by the following series of coupled enzymatic
reactions.
Glycerol + ATP ^ glycerol-l-phosphate + ADP
glycerol kinase
Phosphoenol pyruvate + ADP ^ pyruvate + ATP
pyruvate kinase
Pyruvate + NADH ^ lactate + NAD
lactate dehydrogenase
The final reaction results in a decrease in absorbance at 340 nm as
NAD is formed from NADH and is equivalent to the amount of glycerol
originally present in the sample. A Rotachem II a centrifugal fast analyser
was used for the assays using 50 yl serum and 250 yl reagent. The setting
standard of 300 ymol/1 and high (80 ymol/1) and low (10 ymol/1) quality
controls were prepared from Analar glycerol (BDH, 10118). The inter-assay
C.V. was 3% and the intra-assay C.V. 2%.
47
2.2.5. Haemoglobin A^
Haemoglobin A^ (HbAj)was measured in the routine Diagnostic
T1VI
Laboratory, Ninewells Hospital, using the Glytrac Corning apparatus. The
principle of the test is based on the observation that the non ezymatic
addition of a glucose molecule to the terminal valine residue of both beta
chains of HbA results in a loss of net positive charge. Thus, under the
influence of electroendosmotic flow HbA^ migrates further from the origin
than HbA on an electrophoretic gel. Densitometer scanning of the gel at 420
nm allow quantification of the amount of total HbA^ present. Stable HbAj
was measured after the removal of labile fraction (Labile Removing
Haemolyzing Reagent, Corning Ltd.). The reference range for the non-diabetic
adult population from this laboratory is 4.9 to 7.9%.
2.2.6. Thyroid Function
Thyroxine (T^), tri-iodothyronine (T^) and thyroid stimulating
hormone (TSH) were measured in the routine diagnostic laboratory, Ninewells
Hospital, using 'in-house' radioummunoassay systems. Thyroxine was
measured using a single antibody technique with radiolabeled T^ (SAPU;
Scottish Antibody production unit) precipitated with polyethylene glycol
(PEG). T^ and TSH were measured using a double antibody assay (SAPU).
2.3. ETHICAL APPROVAL
Informed consent was obtained from all subjects and ethical approval
for each study was given by Tayside Health Board Ethical Committee in
accordance with the Declaration of Helsinki.
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2.4. STATISTICAL ANALYSIS
Statistical analysis used standard parametric tests. The students t-test
was used for unpaired observations and the paired t-test for paired
observations. Regression analysis and correlation coefficient of observed and
predicted values were calculated using 'Statspak' computer programme.
k 9
Chapter III
Energy Expenditure in Type I Diabetes Mellitus
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SUMMARY
The hypothesis that insulin has a role in the control of body weight
via alterations in energy expenditure was tested.
Resting metabolic rate (RMR) and the thermic responses to a mixed
meal and the infusion of noradrenaline were measured in nine lean Type I
diabetic subjects initially while poorly controlled on conventional therapy
(CT) and then when optimally controlled on continuous subcutaneous insulin
infusion (CSII). The response to fat supplementation for one week was also
assessed and the results compared to eight non-diabetic subjects who acted
as controls.
1. CSII resulted in marked improvement of glycaemic control and a mean
gain in weight of 3.2 kg.
2. While on CT the RMR in the diabetic subjects was elevated but returned
to predicted values on CSII.
3. CSII corrected the reduced thermic response to the meal after one week
of fat supplementation while controlled on CT.
4. The thermic response to infused noradrenaline was reduced by 50% in
the diabetic subjects irrespective of the degree of glycaemic control.
These findings suggest that the reduction in energy expenditure
contributes to the gain in weight observed on optimisation of diabetic
control.
The wider implications of these findings in relation to an understanding




In Chapter I three recent interrelated areas of research were
reviewed: firstly, the well established association of obesity with insulin
resistance in man and laboratory rodents; secondly, the observations in
animal models of obesity (Rothwell and Stock, 1981; Cunningham et. al.,
1983; Seydoux et. al., 1983) and obese man (Golay et. al., 1982; Ravussin
et. al., 1983) suggesting a requirement for insulin in sympathetic and diet
induced regulatory thermogenesis; and finally the evidence implicating
abnormalities of thermogenesis in the aetiology of obesity (Jung et. al.,
1979; Shetty et. al., 1981). From these three strands a model has been
proposed in which insulin responsiveness may act as part of the mechanism
of controlling energy balance in man. Furthermore, it has been postulated
that abnormalities of insulin sensitivity may itself predispose to obesity
(Felig, 1981).
However, one of the confounding factors in elucidation of the role of
insulin in modulating energy expenditure from both the rodent models and
the human subjects studied to date is the inextricable relationship of insulin
resistance to the obese state per se.
The present study was therefore designed to examine resting energy
expenditure and thermic responses to food and noradrenaline in a group of
non-obese subjects with abnormal glucose tolerance.
Normal weight Type I diabetic subjects were studied and compared to
lean non-diabetic controls.
The two initial questions posed in this study were:
1) Does the lean poorly controlled Type I diabetic
demonstrate similar abnormalities of RMR, and
the thermic responses to food and noradrenaline
infusion, to the obese insulin resistant subject?
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and, if so
2) Are these abnormalities reversible on attainment
of optimal glycaemic control?
In order to assess any role that insulin might have in the adaptive
thermic response to overfeeding, a further study was designed in which the
thermic response was studied before and during a period of excess calorie
ingestion.
An understanding of the hormonal signals that control energy balance
may lead to a method of therapeutically manipulating this homeostatic
mechanism in pathological states such as obesity.
3.2. EXPERIMENTAL PROCEDURE
The study design is illustrated in Figure 3.1. Eight normal weight,
poorly controlled Type I diabetic subjects and eight lean non-diabetic
subjects were studied. The RMR and the thermic response to a mixed meal
and noradrenaline were measured before and during one week of fat
supplementation of the diet in both groups of subjects.
The diabetic subjects were then commenced on continuous subcutaneous
insulin infusion and the measurement of the RMR and thermic responses
were repeated when optimal control had been achieved.
3.2.1. SUBJECTS
All subjects had a stable body weight for at least six months prior to
commencement of the study and none were obese as defined by a body
ConventionalTherapyConti uoussubcutaneous insulininf s on
Fig.3.1.StudyProtocol RMRandthermicresponsetnoradrenaline(RMR+Norad)andMRthermicresponsetmixedm al(RMR+meal)werem asuredb fo endu ingnew ek'ssupplementationofthedi tw thfa(S c ion3.2.4)nd abetica dd beticsubjects.Theresponsesndiabeticsubj tsw rerepeatedfollowingat ainmentfglycaemiccontrolus ngcon inuoussubc taneousins lini fu ion
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mass index (BMI) (weight (kg)/height (m)) of greater than 27. The Report of
the Royal College of Physicians on Obesity (1983) based on the weight for
height tables of the Metropolitan Life Insurance Tables (1960) defines
obesity as a BMI of greater than 30 in men and greater than 28.6 in women.
Two diabetic subjects were cigarette smokers (<10/day) and one
non-diabetic smoked cigarettes (15/day). None of the female subjects had
been breast-feeding for at least two years prior to the study. None of the
subjects were receiving regular oral medication and all were clinically and
biochemically euthyroid (Table 3.1).
3.2.1.1. Diabetic Subjects (Subjects 1-9)
Nine diabetic subjects controlled on a twice daily short and
intermediate acting insulin regimen were recruited from Ninewells Hospital
Diabetic Clinic during the period January to August 1984. Routine screening
for complications of diabetes mellitus was performed in all subjects. All
subjects had normal erect and supine blood pressure measurements, clinical
motor and sensory nerve function, plasma urea and creatinine concentrations
and were negative for urinary protein on Labstix (Ames Ltd.) testing. Subject
No. 8 had background diabetic retinopathy; the remaining subjects had no
evidence of diabetic changes on retinal examination. Subject details are
illustrated in Table 3.2.
Subjects were selected on the basis of poor control (HbAj >10%)
despite good knowledge of diabetes and were enthusiastic about improving
control on continuous subcutaneous insulin infusion.
AgeSexWeightBMI_T.,(yrs)M:F(kg)(k /m)(nmol/1)(nmol/1)
Controls( =8)26.3±3.42:659.8±4.21.71.5±600 15 DiabeticSubj cts(n=8)31.2±8.12:667.9±2.023.879±4.650 26
V-n v«n
Table3.1:Characteristicsofon rols( =8)anddi beticubje ts( =8 . Figuresexpr s edam an±SD. DiabeticsubjectNo.8wasexcludedfr mthisanalysishd otompletethprotocol(S c ion3.3.1.1).Therewerenostatisticallysignificantdifferencesbetwe ncontrolsa dd b ticsubjects.
Subject 1 2 3 4 5 6 7 8 9 Mean ±SD Table
2C-PEPTIDE
























































































Eight non-diabetic subjects with no family history of obesity or
diabetes were recruited from hospital staff and the community and are
hereafter referred to as 'controls'. Subject characteristics are shown in Table
3.1.
3.2.2. C-PEPTIDE MEASUREMENT
To confirm the Type I nature of the diabetic subjects C-peptide was
kindly measured by Dr M. Small, Glasgow Royal Infirmary. (RIA kit for
human C-peptide; Novo Research Institute). Plasma samples were obtained
fasting and also 30 minutes following meal ingestion and frozen and stored
at -20°C. The results are shown in Table 3.2. The normal fasting reference
range for this assay is 0.18 to 0.63 nmol/1. Subject No. 1 had been diagnosed
diabetic five months prior to the study and his results indicate a detectable
but clinically insignificant level of endogenous insulin reserve. As he had
presented acutely in diabetic ketoacidosis he can be considered a Type I
diabetic.
3.2.3. CONTINUOUS SUBCUTANEOUS INSULIN INFUSION
3.2.3.1. General Principles
Continuous subcutaneous insulin infusion (CSII) was initially
developed in the mid-1970's as a method of insulin delivery with the
potential capability of achieving long-term euglycaemia in order to examine
further the role of glycaemic control in the development of diabetic
complications (Pickup et. al., 1978).
Most recently the application of CSII has extended from its limited
use as a research tool in a few specialist centres to that of a practical
alternative method of insulin delivery in selected diabetic patients (Ward,
1984).
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At the time of study design there was considerable enthusiasm based
on the demonstration of marked improvements in glycaemic control and
achievement of normal or near normal HbAj concentrations on CSII
compared to conventional therapy (Calabrese et. ah, 1982; Home et. ah,
1982). However since then several reports have highlighted the disadvantages
of an insulin regimen based solely on short-acting insulin (Anonymous, 1985).
Preliminary short term studies also suggested that the recorded
insulin resistant state observed in Type I diabetic subjects (Del Prato et. ah,
1983) was reversible on optimal glycaemic control using CSII (Lager et. ah,
1983; Yki-Jarvinnen and Koivisto, 1984). Thus CSII was employed as the
method of improving glycaemic control in our subjects.
3.2.3.2. Practical Aspects
On recruitment to the study the potential benefits and hazards of
CSII were discussed with each patient and the need for frequent home
glucose monitoring was emphasised.
Subjects were then admitted to the ward for a period of 2 to 3 days to
commence CSII (Travenol AS6C-U100 pump; Travenol Ltd.) of Actrapid MC
(Novo) insulin and familiarise themselves with the procedures involved.
During this time they were instructed on the adjustment of the single basal
infusion rate to achieve a fasting and early morning nadir (3 a.m.) blood
glucose of between 4 and 6 mmol/1 using BM Stix (Boehringer-Mannheim
Ltd.) in a reflectance meter (Reflolux, Boehringer-Mannheim Ltd.)
Pre-prandial bolus doses were adjusted to achieve a 2 hour post-prandial rise
of 2 mmol/1. During illness subjects were advised to increase the basal rate
of infusion and if necessary to give more frequent boluses. Patients were
instructed to change the infusion site daily, the cannula every 2 days
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and the syringe weekly.
All patients were instructed to keep a supply of conventional syringes
and insulin available in case of pump failure.
Frequent telephone contact was established during the first few weeks
of therapy and thereafter the patients had open access to telephone advice
from me at all times.
Once established on CSII, patients were advised to perform at least
two blood glucose measurements daily and were reviewed at the Clinic at
two-monthly intervals when HbAj was monitored.
3.2.4. Overfeeding
Fat is one of the major components of the Western diet resulting in
excess energy intake and requires minimal expenditure for storage as
adipose tissue (Flatt, 1978).
As facilities were not available for formal supervised overfeeding of
the subjects in a metabolic ward the effect of supplementing their normal
diet with 284 ml (1/2 pint) fresh double cream per day for seven days on the
RMR and thermic responses was examined. This is equivalent to an energy
rise of 5.23 MJ/day (1270 Kcal/day) and has fat:protein:carbohydrate ratio of
24:0.7:1.0. As this "overfeeding" was unsupervised and the precise calorie
intake could not be documented, it is referred to hereafter as "fat
supplementation".
The thermic responses to the meal and noradrenaline were measured
on the sixth and seventh days of fat supplementation in random order. The
RMR was measured on both mornings and expressed as the mean of these
two measurements.
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3.2.5. Insulin Regimens for Diabetic Subjects on Study Days
3.2.5.1. RMR and Noradrenaline Infusion
- On Conventional Therapy
Subjects on conventional therapy were instructed to inject their
normal dose of short acting insulin before the evening meal of the day prior
to study. The injection of intermediate acting insulin was delayed until 2100
hours to prevent fasting hypoglycaemia the following morning during
measurements.
RMR and the thermic response to noradrenaline were measured prior
to the morning injection of short and intermediate acting insulins which were
given at the end of the tests 20 minutes prior to breakfast.
- On CSII
Subjects continued the basal rate of infusion throughout the
measurements and the morning pre-prandial bolus of short acting insulin was
given prior to breakfast at the termination of measurements.
3.2.5.2. Meal
- On Conventional Therapy
Subjects injected their normal doses of short and intermediate acting
insulins following the measurement of RMR and 20 minutes prior to
ingestion of the meal.
- On CSII
The morning pre-prandial bolus of short acting insulin was delivered
following RMR measurement and 20 minutes prior to meal ingestion.
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3.2.6. Insulin Withdrawal
In order to determine that the effects of CSII on resting metabolic
rate were the result of insulin delivery and not merely one to 'training' of
the subjects to the procedures involved, the RMR was measured on one
further occasion 11 hours following the withdrawal of insulin.
Subjects were instructed to remove the infusion pump and cannula at
10 p.m. the evening prior to having their RMR measured at 9 a.m. The
subjects were then recommenced on CSII and normoglycaemia restored
within 4-5 hours. The RMR on conventional therapy and CSII was then
compared to that following insulin withdrawal.
3.3. RESULTS
3.3.1. Continuous Subcutaneous Insulin Infusion
The results of CSII are presented in two sections.
Firstly the experience, based on the nine patients studied, with this
method of insulin delivery will be reported with reference to patient
acceptability, glycaemic control and complications of CSII during the first
124 patient months.
Secondly, the levels of glycaemic control that were observed at the
time the subjects' RMR and thermic responses were repeated on CSII are
reported.
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3.3.1.1. General CSII Experience
Patient Acceptability
Eight of the nine diabetic subjects found CSII a highly acceptable
method of insulin delivery which not only resulted in significant objective
improvement of glycaemic control but also subjective improvement in
lifestyle with increased flexibility of mealtimes, leisure and work activities.
Complications - Local cutaneous reactions. One subject (No. 8), who worked
up to 18 hours per day as a market gardener, suffered persistent discomfort
at the cannula insertion site and despite the use of alternative insertion
sites (loin, thigh) was withdrawn from CSII after 10 months when a
subcutaneous abscess developed at a needle insertion site. As this subject
failed to achieve a HbAj of below 10% the metabolic studies on CSII were
not performed and he was excluded from further analysis.
Five months following completion of the study, subject No. 6
developed abdominal lipohypertrophy which resolved on increased rotation of
injection sites.
Hyperglycaemia
To date (dune 1986) none of the subjects have had an episode of frank
ketoacidosis but based on subjects' own records of home blood glucose
monitoring acute minor episodes of loss of glycaemic control with blood
glucose concentrations of up to 18 mmol/1 were relatively common. Home
blood glucose estimations of greater than 14 mmol/1 were recorded at a
frequency of one episode per 2.8 patient months during the first 124 patient
months of CSII.
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The vast majority of these episodes were associated with failure of
insulin delivery as a result of blocked cannulae, air in the cannulae or luer
lock leakage but a significant proportion were due to "patient malfunction"
with failure to change batteries, fill the syringe or omission of pre-meal
boluses. It is a credit to the patients' diligent home glucose monitoring that
all these episodes were aborted within 12 hours.
Hypoglycaemia
This can be considered under two headings - mild symptomatic
(adrenergic symptoms only) and severe hypoglycaemia.
Mild symptomatic hypoglycaemia - Data collected retrospectively from
patients' home glucose monitoring and diary recording of mild hypoglycaemia
tends to be, by definition, selective and therefore these figures have not
been formally quantified in terms of episodes per patient month.
However, subjectively the subjects noted an increased incidence of
mild hypoglycaemia on CSII compared to conventional therapy, especially in
the early months of treatment due to miscalculation of the pre-prandial
bolus in relation to the carbohydrate content of the meal and exercise.
Most patients noted a different character to the reactions; symptoms
such as perioral parasthesiae - which had not been previously noted by five
of the nine subjects on conventional therapy - became a prominent
premonitory feature. Symptoms such as this tended to be slower in onset and
consequently mild reactions could be swiftly aborted with carbohydrate.
Severe hypoglycaemia - This is considered as a hypoglycaemic reaction
outwith the control of the patient requiring intervention from either a
relative and/or a medical attendant due to neuroglycopaenic symptoms.
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With this clearly defined end point, quantification of episodes can be
attempted. In 124 patient months three of the nine subjects developed severe
hypoglycaemic reactions requiring intramuscular glucagon and/or hypertonic
intravenous glucose. This represents a rate of one episode per 31 patient
months in this small sample. Two of the subjects (Nos. 5 and 6) had never
previously experienced severe hypoglycaemia.
Each of these three episodes was precipitated by miscalculation of the
pre-prandial bolus in relation to meal size and exercise and two were further
exacerbated by alcohol.
Pregnancy - It is interesting to note that one of the subjects (No. 5) became
pregnant after seven months on CSII and was maintained in CSII throughout
the pregnancy with no episodes of metabolic decompensation. The HbAj at
estimated time of conception was 7.8% and the mean HbAj during pregnancy
(mean ± SD of six estimations taken at 8, 14, 18, 22, 28 and 34 weeks) was
7.6 ± 0.4%. The final trimester of pregnancy was complicated with
polyhydramios and foetal heart slowing and a baby girl was delivered at
Caesarian section at 37 weeks gestation weighing 3.9 kg. This figure is above
the 95th centile for later-born girls with adjustments for maternal weight
and height according to the Tables for Tanner and Thomson (1970).
3.3.1.2. Glycaemic control
The mean HbAj was significantly lower on CSII compared to




The mean HbAj taken on the first morning of repeat metabolic
studies (RMR and thermic responses) is shown in Table 3.3. HbAj had
significantly decreased (pc.OOl) despite similar total daily insulin dose and
fasting blood glucose was similar to that in the non-diabetic control group
(Table 3.4). The median time between study on CT and CSII was 5.3 months
with a range of 3.5 to 8 months.
3.3.2. Weight
The weight of the eight diabetic subjects who completed the study
rose significantly on CSII. These results are shown in Table 3.3 and refer to
the body weight measured on the first morning of metabolic study on CT and
CSII.
The mean change in body weight during the first nine months of CSII
is shown in Figure 3.3. Following completion of the metabolic studies
further dietary advice was given to the subjects to reverse this trend and
therefore only the data during the first nine months is shown in this Figure.
Subject No. 5 was excluded from this analysis as she had become pregnant
(Section 3.3.1.1).
3.3.3. Resting Metabolic Rate
3.3.3.1. On normal diet
The poorly controlled diabetic subjects had an increased RMR
compared with predicted values (Table 3.5). The estimated difference was
346 KJ (83 kcal) per 24 hours with 95% confidence limits of 18.7 and 672.5
KJ (4.5 and 160.7 kcal). The RMR decreased to within the predicted range
with CSII despite a significant increase in weight. The decrease with precise
glycaemic control reduced energy expenditure by an estimated 374.4 KJ
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FatSupplemented 4.25±0 19 4.86+0.24 4.81±0 37
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156.6 kcal)). The non-diabetic subjects showed a good correlation between
observed and predicted values (r = 0.93, p<0.0005).
3.3.3.2. RMR on fat supplemented diet
There was no significant change in the RMR with fat supplementation
in either the non-diabetic subjects or the diabetic subjects during
conventional treatment or CSII (Table 3.5).
3.3.3.3. Insulin withdrawal
Six subjects agreed to take part in the insulin withdrawal study (Nos.
1, 2, 3, 6, 7, and 9). Fasting plasma glucose rose over three-fold on insulin
withdrawal and was associated with a 16% elevation of the RMR (Fig. 3.4).
With the small numbers involved there was no correlation (r = 0.17)
between the magnitude of the rise in plasma glucose and that of the RMR.
3.3.4. Thermic Response to the Meal
3.3.4.1. Normal diet
There was no significant difference in the energy content of the test
meal between diabetic (1.80 ± 0.13 MJ) and control subjects (1.97 ± 0.16 MJ).
Following ingestion of the meal, the control group and the diabetic subjects
on CT and CSII had similar incremental thermic responses (Table 3.6 and
Figure 3.5).
3.3.4.2. Fat supplemented diet
When supplemented with fat the control group showed no change in
the thermic response to the meal. In contrast, the diabetic subjects on
conventional therapy exhibited a significant reduction of the thermic
response during the second hour (p<0.05) which was 57% less than that
5.8- 5.6- 5.4- 5.2-
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observed in the same subjects before fat consumption. When these subjects
had attained optimal glycaemic control on CSII, they then exhibited no
significant change in their thermic response to the meal during fat
supplementation.
3.3.5. Glucose Response to the Meal
The fasting plasma glucose and following ingestion of the meal is
shown in Figure 3.6. The mean plasma glucose was significantly lower at all
times on CSII compared to CT and the mean fasting plasma glucose on CSII
was not significantly different from the control subjects. The plasma glucose
however following meal ingestion in the diabetic subjects on CSII still
remained significantly higher than in the non-diabetic controls.
The accumulative incremental rise of glucose in response to the meal
(Table 3A) was 5.5-fold higher in the poorly controlled diabetic subjects
compared to controls. On CSII this figure still remained five-fold greater
than in the controls.
Fat supplementation resulted in a significant rise in fasting blood
glucose in the diabetic subjects on CT but no change (p<0.02) during CSII or
in control subjects (Table 3A).
3.3.6. Thermic Response to Noradrenaline
There was a significant increase in energy expenditure during
noradrenaline infusion in all subjects.
Seven of the eight diabetic subjects demonstrated a blunted response
to infused noradrenaline compared to controls (Fig. 3.7 and Table 3.6).
One diabetic subject (No. 6) was excluded from this analysis as the
infusion of noradrenaline produced a subjective feeling of stress associated




















Fig. 3.7. Thermic response to noradrenaline infusion before (A) and
during fat supplementation (B) in 8 non diabetic subjects
(A) and in 7 diabetic subjects on conventional therapy (■; CT)
and on continuous subcutaneous insulin infusion (•; CSII).
Diabetic vs non diabetic; **p<0.02, ***p<0.01
Mean ± SEM.
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inaccurate assessment of the thermic response which was almost 50% greater
than the normal response in the control subjects (41.8 KJ compared to 27.1
K3). Noradrenaline infusion was well tolerated by all other subjects.
The incremental thermic response shown by the remaining diabetic
subjects on CT was 54% lower than that shown by the control group and this
blunting was reproduced both before and during fat supplementation.
Further, the thermic response did not improve on CSII and remained 46%
lower than that in controls. When repeated during fat supplementation there
was no significant alteration in the response observed in any of the groups
(Fig. 3.7 and Table 3.6).
3.3.7. Biochemical Response to Noradrenaline
3.3.7.1. Glucose
Noradrenaline infusion resulted in a significant rise in mean plasma
glucose at 15, 30 and 45 minutes in the control subjects. There was also a
rise in mean plasma glucose in the diabetic subjects but this did not reach
statistical significance (Fig. 3.8). As subcutaneous insulin continued to be
absorbed (CT) and infused (CSII) the response was more variable, with one or
two individual subjects in each group demonstrating a net fall in blood
glucose during infusion. There were no significant differences when the rise
of glucose between the control and diabetic subjects were compared.
Diabetic subjects on normal diet had a significantly greater rise in plasma
glucose on conventional therapy than on CSII (p<0.05; Table 3.7).
3.3.7.2. Free fatty acids
Basal values and the rise in the fatty acids in response to
noradrenaline were similar in all groups of subjects studied both in normal
diet and during fat supplementation (Fig. 3.9(a) and Table 3.7).
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Intensification of physician-patient contact, the increase in practical
knowledge of the tripartite relationship between diet, insulin and exercise
and the delivery of insulin via continuous subcutaneous insulin infusion all
combined to achieve the goal of marked improvement in glycaemic control
in this study approaching the non-diabetic state.
As this study was not designed to examine the efficacy of CSII as a
method of insulin delivery compared to conventional therapy it is unfair to
attempt to draw comparisons from the limited experience resulting from
these few highly motivated subjects to the result of other studies comparing
CSII to CT.
However, some broad conclusions can be drawn. The three major
complications of CSII - cutaneous, hyperglycaemia and hypoglycaemia - have
all been highlighted in other studies.
Cutaneous complications at the site of needle insertion have been
well described (Pietri and Raskin, 1981; Levandowski et. al., 1982). As
infection at the site of insulin injection on CT is extremely rare, the report
in one major study involving 161 patients of infected needle sites occurring
in 29% of patients is of concern (Meckelenberg et al., 1984).
In the present study the clinical impression was that as the subjects
became more familiar with the procedures involved in CSII, "short cuts" in
aseptic technique and cannula care became more apparent. Although this has
not led to local abscess formation, it has certainly contributed to an increase
in the number of episodes of hyperglycaemia due to line blockage or
disconnection, omission of meal time boluses and failure to check the
amount of insulin in the syringe or the state of charge of the battery.
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No episodes of frank ketoacidosis have been recorded in the remaining
eight patients on CSII; other workers have estimated the incidence of this
complication at one episode per 78 patient months (Meckelenberg et. al.,
1984) to one episode per 32 patient months (Peden et. al., 1984). The lack of
experience of ketoacidosis in the present study once again probably reflects
the small numbers monitored intensively over a relatively short period of
time.
The other major problem is hypoglycaemia. In several studies overt
hypoglycaemia occurred no less frequently on CSII compared to CT (Kroc
Collaborative Study Group, 1984; Lauritzen et. al., 1983; Home et. al.,
1982). In the largest reported series of patients treated long term with CSII
hypoglycaemic coma occurred with a frequency of one episode per 175
patient months and was slightly less common than in a group of 165 patients
on conventional therapy (Meckelenberg et. al., 1984).
The three episodes of hypoglycaemic coma encountered in the short
period of the present study contrasts with this experience but the sample
size and duration of treatment obviates the drawing of conclusions.
Since the report of Steele and West (1985) which illustrated the
potential deficiencies of an insulin regimen based solely on short acting
insulin during pregnancy and the observations of Knight et. al. (1985) of the
rapidity at which acute metabolic decompensation can occur on CSII when
insulin supply is interrupted would make the author reluctant to expose a
diabetic woman to the risks of CSII during pregnancy in future. The mild
macrosomia of the infant of subject No. 5 despite adequate glycaemic
control, as evidenced by HbAj estimation, may be a reflection of minor
episodes of loss of control due to transient interruption of insulin delivery.
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As evidence accumulates that similar levels of glycaemic control can
be achieved using an intensified regimen based on long acting insulin with
pre-prandial injections of short acting insulin (Calabrese et. al., 1982)
without the risk of acute metabolic decompensation due to mechanical
failure of insulin delivery, the practical role of CSII in the management of
the Type I diabetic subject likely to emerge is that of a useful adjunct to
achieve periods of optimal control in motivated patients under intense
supervision.
In conclusion, although CSII is a highly attractive and convenient
method of insulin delivery from the patients' point of view, in terms of its
initial aim of achieving long term (i.e., over a period of 20-30 years)
euglycaemia, its role remains limited.
3.4.2. Resting Metabolic Rate
Quantitatively the RMR accounts for 65 - 75% of man's total 24 hour
energy expenditure (Oequier, 1984). Hence relatively small changes in the
RMR may have a substantial accumulative effect on long term energy
balance.
One can calculate from the present study that those on CSII had a
reduction in RMR amounting to the equivalent of 346 KJ (83 Kcal) per 24
hours. This reduction in RMR occurred despite a significant increase in body
weight, which would itself have the effect of elevating the RMR, thus
making this trend even more significant. If dietary intake had remained
constant then this amount of energy would have been availale for storage
hence predisposing to weight gain. Together with the reduction in energy
"loss" due to glycosuria this may partly explain the significant gain in
weight that occurred in the diabetic subjects during CSII despite similar
insulin dosage.
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Home et. al. (1982) have also observed this phenomenon on CSII and in
the 10 subjects studied weight significantly increased from a mean of 67.6 kg
to 69.1 kg after six weeks of CSII and remained significantly elevated for
the duration of the study. This reduction in RMR on CSII does not seem to
be an adaptive process occurring over a period of time as the subjects on
CSII showed a striking rise in RMR following the overnight withdrawal of
insulin, thus suggesting that the restoration of a euglycaemic state is the
major determinant of the abolition of this abnormality in Type 1 diabetic
subjects. It is interesting to note, however, that this phenomenon was not
noted in streptozotocin induced diabetes in rats. Rothwell and Stock (1981)
found similar resting oxygen consumption in diabetic (13.3 ± 0.3
ml/min/W^"') and non-diabetic (12.8 ± 0.5 ml/min/W^*^^) rats.
An elevation of RMR on acute insulin withdrawal in already poorly
controlled Type I subjects has also been shown by Nair and colleagues (1984).
In this study hyperglycaemia (mean plasma glucose 19.3 mmol/1) associated
with mild acidosis resulted in an elevation of the RMR 18% above that
observed in the same subjects when euglycaemia was achieved (mean plasma
glucose 5.8 mmol/1) using intravenous insulin.
The important point however arising from the present study is that
the observed elevation of the RMR performed under the Harrow group's
laboratory extremes of hyperglycaemia and euglycaemia is also observed in
Type I diabetic subjects at levels of glycaemic control commonly encountered
in clinical practice.
The mechanisms responsible for the increase in the RMR remain
unclear. The metabolic acidosis associated with the uncompensated diabetic
states cannot completely explain the increase in energy expenditure as in
the study of Nair et. al. (1984), even those subjects who had a normal serum
bicarbonate concentration had an elevated RMR.
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As demonstrated in the present study with the infusion of noradrenaline,
catecholamines can exert considerable influence in the RMR in man.
Although diabetic ketoacidosis is associated with an elevation of these
circulating hormones (Schade and Eaton, 1979), Alberti et. al., ( 1975)
demonstrated that withdrawal pf insulin for 41 hours was not associated with
a significant elevation of catecholamines. These hormones are therefore
unlikely to be making a major contribution to the observed elevation in
RMR.
The other major hormonal insulin antagonists which may be elevated
during poor diabetic control are Cortisol and growth hormone (Schade and
Eaton, 1979). Nair et. al. (1984) however found no significant correlation
with these hormones and energy expenditure in their study. A significant
correlation however was found with plasma glucagon concentration but this
does not prove that glucagon is responsible for the raised energy
expenditure and may merely represent a secondary phenomenon.
The biochemical pathways determining rates of fat, carbohydrate and
protein synthesis and oxidation and the complex cycling of substrates from
one pathway to another constitute a major component of resting energy
expenditure.
The Harrow Group (Nair et. al., 1983b) has demonstrated increased
rates of both protein synthesis and degradation during poor diabetic control
and have more recently (Nair and Halliday, 1985) demonstrated a positive
correlation between the rate of protein synthesis and energy expenditure in
non-diabetic subjects. This may be one of the factors contributing to the rise
in RMR.
An increased basal rate of lipolysis, and subsequently fat oxidation, is
suggested in the poorly controlled diabetic subjects by the significantly
greater concentrations of fasting plasma glycerol and the tendency, which
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did not reach statistical significance (p = .06), for a lower respiratory
quotient on CT (0.77 ± .02) which reverted to normal on CSII (.83 ± .02). This
factor too may also contribute to the elevation in RMR.
The final factor which should be considered is the energy expenditure
involved in the increased rate of gluconeogenesis in poorly controlled
subjects (De Fronzo et. al., 1985).
Thus the significant elevation in RMR observed in the poorly
controlled diabetic state may be due to a number of factors and if problems
of weight gain on improvement of glycaemic control are to be avoided
appropriate dietary advice should be instituted.
3.^.3. Thermic Response to the Meal
The thermic effect of food makes a significant contribution to the
remaining 20-35% of total daily energy expenditure.
In the present study there was no significant difference in the thermic
response to the mixed liquid meal when either the diabetic or non-diabetic
subjects were ingesting their normal diet irrespective of the degree of
glycaemic control.
If insulin has a role to play in determining the thermic response to a
physiological mixed meal one would have expected the hyperglycaemic (and
thus relatively insulin deficient) subjects on CT to have a lower response
than during CSII and when compared to non-diabetic controls. The present
results, however, are in contrast to the work of Golay and colleagues (1982)
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who demonstrated a progressive diminution of the thermic response to a 100
g oral glucose load with increasing insulin resistance (Fig. 1.4(b)).
The concurrent finding of blunted thermic responses to glucose loads
(Pittet et. al., 1976; Schutz et. al., 1984b), high protein meal (Kaplan and
Leveille, 1976), fat (Swaminathan, 1985) and mixed meals (Shetty et. al.,
1981; Bessard et. al., 1983; Schutz et. al., 1984a) in obese subjects has led to
the hypothesis that insulin acts as an important mediator of these
abnormalities in the predisposition of some individuals to obesity (Felig,
1984).
An almost equal number of other workers however have failed to
demonstrate such abnormalities in obese subjects (Bradfield and Oourdan,
1973; Sharief and Macdonald, 1982; Nair et. al., 1983; Welle and Campbell,
1983a; Swaminathan et. al., 1985).
These conflicting findings may be due to a number of factors
including the calorimetric method used, the duration of study and different
composition of the test meal. Jequier (1984) has recently demonstrated that
these abnormalities may only occur in subgroups of obese subjects and
therefore the individual subjects studied provide another variable in this
field of conflicting data.
To return to the role of insulin however, close perusal of the
literature might suggest that the data from the present study are not
incompatible with the previous findings in obese and Type II diabetic
subjects. Firstly the work of Golay et. al. (1982); Pittet et. al. (1976) and
Schutz et. al. (1984b) was concentrated solely on the thermic response to an
unphysiological stimulus of 100 g or 50 g oral glucose loads. As diminished
glucose oxidation is one of the cardinal features of insulin resistant states
(Felber et. al., 1981), a diminution of the thermic response is thus not
surprising. When the data of Golay et. al. (1982) (Fig. 1.4(b)) is closely
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examined the differences between the grossly obese subjects with impaired
glucose tolerance and Type II diabetic subjects characterised by an
exaggerated insulin response and the non-obese subjects reduces from a
significance of <0.05 and <0.001 respectively to statistically indistinguishable
from lean controls when the correction for unmetabolised glucose is made.
Pittet's data documents a 40-45% reduction in the rate of carbohydrate
oxidation in the obese group compared to controls. The data of Schutz et. al.
(1984b) is also hard to reconcile with a primary role for insulin in the
generation of the thermic response as when the obese subjects were studied
after weight loss the corrected thermic response to glucose, expressed as a
percentage of the energy load, fell further from 6.2% to 3.4% despite return
of glucose tolerance to normal. The same group have also demonstrated that
the apparent diminution of the thermic response to infused glucose can be
corrected by establishing similar rates of cellular glucose uptake using the
euglycaemic hyperinsulinaemic clamp technique (Ravussin et. al., 1985).
When studies using a more physiological meal are examined a similar
pattern emerges - the persistence of thermic abnormalities in obese subjects
despite the return of insulin sensitivity is indistinguishable from that of lean
controls when weight loss is achieved (Shetty et. al., 1981; Bessard et. al.,
1983).
Thus from the present study it is likely that the absence of a
demonstration of a thermic abnormality in the diabetic subjects was due to a
number of factors. Firstly despite the five-fold greater rise in plasma
glucose following the meal, indicative of unmetabolised glucose, this alone
was not of sufficient magnitude to cause a significant diminution of the
total thermic response resulting from the processing of all the constituents
of the mixed meal.
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Secondly, when the literature is examined critically concerning
thermic abnormalities to food in obese and Type II diabetic subjects it must
be concluded that these abnormalities are only indirectly mediated in
insulin.
3.4.4. Thermic Response to Noradrenaline
The thermic response to noradrenaline also contributes to the
remaining 24 hour energy expenditure and although the magnitude of this
component is difficult to precisely quantify as it fluctuates according to the
ambient sympathetic tone, at least 5% and up to 10% of total daily energy
expenditure may be accounted for by this component.
In the present study the thermic response to noradrenaline was
reduced by over 50% in the diabetic subjects irrespective of their degree of
glycaemic control. Although the total daily energy "deficit" due to these
blunted responses cannot be calculated from the present study, one can
speculate that it is unlikely they are of sufficient magnitude to outweigh the
effect of the raised RMR in poorly controlled diabetes mellitus. However, on
attainment of optimal glycaemic control these blunted responses would be
one further factor predisposing to weight gain if dietary intake remained
unchecked.
What is the mechanism of this thermogenic abnormality in the Type I
diabetic subjects?
Firstly, a consideration of the animal models in which blunted
noradrenaline responsiveness has been associated with diabetes would
suggest that altered insulin sensitivity in the diabetic subjects might be a
contributory factor. As reviewed in Section 1.3.3.4, Rothwell and Stock
(1981) demonstrated a requirement for insulin in the thermogenic adaptation
to cafeteria feeding in rats. Of particular interest in view of the results of
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the present study, they also demonstrated that the thermic response to
noradrenaline in poorly controlled streptozotocin diabetic rats on normal
stock diet (blood glucose 19.2 + 1.0 mmol/1) was blunted by over 50% (rise in
oxygen consumption 3.3 ml/min W^*^) compared to non-diabetic rats (7.6
ml/min/W^*^). However following insulin replacement (blood glucose
unspecified) the thermic response returned to normal (6A5 ml/min/W^"^).
This suggested a direct requirement for insulin not only in the adaptive
response to cafeteria feeding but also in the normal thermic response to
noradrenaline on normal diet. This contrasts with the persistent blunting of
noradrenergic thermogenesis despite insulin replacement using CSII in the
present study. Cunningham et. al. (1983) and Seydoux et. al. (1983) also
demonstrated abnormalities of brown adipose tissue metabolism in diabetic
rats and the results of the former workers demonstrated that these also
predisposed to weight gain.
When studies reflecting noradrenaline responsiveness and insulin
sensitivity in man are considered similar conflicting results are found. The
presence (Jung et. al., 1979) and absence (Katzeff et. al., 1986; Finer et. al.,
1983) of blunted thermic responses to noradrenaline infusion in obese
hyperinsulinaemic subjects have both been documented. In all these studies
the subjects were also examined following significant weight loss and there
was no improvement (dung et. al., 1979), no change (Katzeff et. al., 1986)
and in fact a blunting of the response (Finer et. al., 1985) on the attainment
of significant weight reduction. Jung et. al. (1979) hypothesised from their
findings that the thermic defect to noradrenaline was an inherent
abnormality in the obese state whereas Finer's group attributed the blunting
to their extreme hypocaloric (390 kcal; 1.6 MJ/day) diet. With the recent
finding that blunting the thermic response to noradrenaline in lactating
subjects (Illingworth et. al., 1986) was associated with increased insulin
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sensitivity during lactation the case for a simple relationship between
noradrenergic thermic responsiveness and insulin sensitivity becomes less
tenable. Further, Bazelmans et. al. (1985) failed to find any correlation
between insulin sensitivity and noradrenaline flux in obese subjects before
and after weight loss.
Thus, when the evidence from human studies is examined critically the
hypothesis proposed by Rothwell and Stock (1981) for a significant
thermogenic role for insulin is not supported in man as these thermic
abnormalities have been demonstrated in both increased (lactation), normal
(post-obese) and decreased (obese) states of insulin sensitivity.
The findings from the present study, which demonstrated that despite
marked changes in glycaemic control persistence of thermic abnormalities
occurred, would tend to indicate that other mechanisms than solely insulin
are concerned.
At this point it is worth examining the evidence for changes in insulin
sensitivity during CSII for although I have demonstrated a marked
improvement in glycaemic control on CSII on similar dosage of insulin, this
does not necessarily infer an improvement in insulin sensitivity.
Initial reports suggested that the insulin resistance associated with
Type 1 diabetes (Del Prato et. al., 1983) was reversible on improvement of
glycaemic control with CSII (Lager et. al., 1983). However a review of the
current literature demonstrates that although some workers have demonstrated
an improvement of insulin mediated glucose disposal during CSII (Lager et.
al., 1983; Simonson et. al., 1985; Beck-Nielson et. al., 1984; Yki-3arvinnen et.
al., 1984), others have failed to do so (Simonson et. al., 1982). The values for
glucose disposal however remain at best 2 5 96 lower (Lager et. al., 1983) in
Type I diabetic subjects on CSII than that of the respective non-diabetic
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To further examine the role of insulin resistance in determining the
blunted thermic responses to noradrenaline a further experiment was
attempted.
The biguanide derivative, metformin historically has been used in
addition to insulin therapy in poorly controlled Type I diabetic subjects in
attempts to reduce insulin dosage (Duncan and Seaton, 1962). More recently
(Gin et. al., 1985) metformin has been shown to increase insulin mediated
glucose disposal in Type 1 diabetic subjects suggesting that this agent may
be used to pharmacologically decrease insulin resistance. Six of the diabetic
subjects in the present study, after completion of the protocol agreed to
take metformin 500 mg three times daily with meals for fourteen days,
whilst receiving continuous subcutaneous insulin infusion. Only three of the
subjects however managed to complete fourteen days treatment, the others
developing nausea and abdominal upset necessitating withdrawal of
metformin. In these subjects the thermic response to noradrenaline was
measured before and on the fourteenth day of metformin therapy. Metformin
improved the thermic response to noradrenaline in all three subjects as
shown below.




Thermic response to noradrenaline (KJ) on CSII and with the addition
of metformin 500 mg t.d.s.
Although insulin mediated glucose disposal was not assessed before
and during metformin therapy it is interesting to speculate whether a change
in insulin sensitivity might be implicated in the improvement of the thermic
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response. In contrast, metformin does not increase the thermic response to
noradrenaline in Type II diabetic subjects (Section 4.3.6.) but these subjects
already had a normal thermic response to this catecholamine prior to
metformin therapy. Thus, although studies such as this will need to be
extended before any firm conclusions can be drawn, perhaps these results
give some credence to the past practice of administering biguanide to obese
subjects poorly controlled on insulin (Duncan and Seaton, 1962).
Therefore, if insulin is not a major determinant of these altered
thermogenic responses in the present study what other factors may be
involved?
As about 50% of the thermic response effect of noradrenaline is
related to lipolysis and fat oxidation (Havel et. al., 1964) a diminution of the
lipolytic response to catecholamines in the obese, lactating and the present
diabetic subjects might explain the differeing thermic responses. Conversely,
an insulin resistant state in obesity or poorly controlled diabetes should
predispose to enhancement of the thermic response by enhancing lipolysis.
However, the obese (Jung et. al., 1979), lactating (Illingworth et. al., 1986)
and the Type I diabetic subjects demonstrated similar rates of lipolysis
despite marked blunting of the thermic responses.
Noradrenaline infusion has been employed as a model for non-
shivering thermogenesis and brown adipose tissue metabolism in man (James
and Trayhurn, 1981). The hypothesis that these thermic differences are due
to diminished brown adipose tissue activity in adult man are discussed in
Chapter V.
Recently the work of Astrup et. al. (1985a) in man has demonstrated
that chronic administration of the sympathomimetic agent, ephedrine, may
enhance thermogenesis. 50% of this heat production appears to be generated
in skeletal muscle (Astrup et. al., 1985b), with a negligible contribution from
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perirenal brown adipose tissue and may involve activation of 62 receptors
(Fagher et. al., 1986). Substrate cycling and kinetics within the metabolic
masses of skeletal muscle and liver (Berry et. al., 1985) may partly account
for the differences noted by the differential shunting of substrates to either
energetically efficient or wasteful pathways in different physiological
(lactation) or pathological (obesity and diabetes mellitus) states.
Once the precise biochemical mechanisms and the tissue or tissues
involved in the generation of the normal thermic response to noradrenaline
are elucidated then and only then will the mechanism and significance of the
blunted responses to catecholamines be fully understood.
3.4.5. Effect of Fat Supplementation
Since Neumann demonstrated in 1902 the ability to maintain his body
weight within narrow limits despite increasing his daily energy intake from
7.4 MJ to 10 MJ over a period of 3 years, the elusive concept of
"luxuskonsumption" has been investigated by many groups. Although almost
all studies agree on the finding of an elevation of the RMR during
overfeeding (Section 1.4.1) opinion is divided as to whether there is evidence
for an adaptive mechanism for the dissipation of excess calories as heat in
man.
In the present study there was no demonstrable change in the RMR or
thermic response to noradrenaline in either the diabetic or control groups
during fat supplementation. The study design resulted in an approximately
30 - 50% increase in energy intake mainly in the form of fat which was
sufficiently acceptable to assure compliance and not lead to deterioration in
control in the diabetic subjects over a short period of time. It is likely,
however, in retrospect, that the duration of fat supplementation was
insufficient to demonstrate a significant change in energy expenditure, but
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does demonstrate the inability of a group of individuals to rapidly
compensate for an increase in energy intake by a measurable intake in
energy expenditure. Dalosso and James (1984) in a meticulously controlled
study using 24 hour whole body indirect calorimetry and accurate (to within
1 g) weighed intakes, overfed eight men with a similar amount of fat as used
in the present study (5 MJ) for a period of one week. Their results however
demonstrated only a small thermogenic component in excess of that
predicted from the theoretical energy cost of fat storage and illustrate the
difficulties involved in the accurate assessment of regulatory thermogenesis
in man.
The apparent blunting of the thermogenic response to food in the
poorly controlled diabetic subjects following fat supplementation resulted in
a diminution of energy expenditure in the region of 30 KJ (7 kcal) in the 2
hour period. Although post-prandial thermogenesis may continue for up to 24
hours following ingestion this energy deficit may have been appreciably
greater if we had measured the expenditure resulting from three main meals
and associated snacks over a 24 hour period using direct calorimetry.
The mechanisms for this blunting in the second hour cannot be
conclusively determined from this study. Two factors, however, may be
significant. When the poorly controlled diabetic subjects were supplemented
with fat, the mean blood glucose concentration fasting and during the
post-prandial period tended to be 3 to 4 mmol/1 higher compared to the
same subjects when studied on normal diet and during CSII (Figure 3.6). Fat
overfeeding may have induced a degree of insulin resistance (Olefsky, 1976)
and thus resulted in diminished glucose oxidation.
The other factor that was not assessed in the present study was that the
amount tff unmetabolised glucose in the glucose space and the amount lost in
the urine and thus unavailable for glucose oxidation was greater in the
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fat-fed poorly controlled diabetic subjects. The energy deficit of 30 KJ
would have to be accounted for by an urinary loss of glucose of 2 g in the 2
hour period.
3A.G. Conclusions
In conclusion, it appears that adequate glycaemic control with CSII
does not correct all the metabolic abnormalities of Type I diabetes mellitus.
These patients seem to be at a disadvantage regarding energy balance when
glycaemic control is improved. In this setting the RMR increases appreciably
and if a reduction in intake is not advised then weight increase is likely to
ensue. From a wider viewpoint these data also suggest the role of insulin in
the control of thermogenic responses to mixed meals and noradrenaline in
man is a relatively minor one, in that apparently normal thermic responses
to food occurred despite poor glycaemic control and conversely blunted
thermic responses to noradrenaline occurred during optimal control on CSII.
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Chapter IV
Energy Expenditure in Type II Diabetic Subjects
on Oral Hypoglycaemic Therapy
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SUMMARY
The treatment of the obese diabetic subject with metformin tends to
promote weight loss whereas treatment with sulphonylurea derivatives tends
to result in weight gain.
In order to assess whether these changes in weight result from
alterations in energy expenditure, the resting metabolic rate and the
thermic responses to food and noradrenaline were measured in seven Type II
diabetic subjects while on metformin and sulphonylurea therapy.
The resting metabolic rate and thermic responses were similar on
metformin and sulphonylurea therapy and these responses did not differ
significantly from that predicted for non-diabetic subjects.
It is concluded that Type II diabetic subjects do not exhibit any
specific abnormality of energy expenditure while on therapy and that
metformin does not facilitate weight loss by enhancing energy expenditure.
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4.1. INTRODUCTION
Obesity is one of the major factors in the aetiology of Type II
diabetes mellitus and weight loss through carbohydrate and caloric
restriction results in some improvement in glycaemic control in the majority
of subjects. However, in clinical practice, many patients fail to achieve
adequate weight loss and improvement of glucose tolerance despite alleged
restriction of intake.
Controversy rages as to whether this is merely due to dietary
indiscretion on the part of the subject or to whether there is an inherent
abnormality of energy expenditure in these subjects which predisposes to
failure of weight loss. The consistent demonstration of an elevation of
energy expenditure in obese subjects compared to matched lean subjects
when measured as the RMR (James et. al., 1978; Halliday et. al., 1979; Finer
et. al., 1986) or as total daily energy expenditure (Bessard et. al., 1983;
Prentice et. al., 1986) lends support to the concept of the "obese deceiver"
(Southgate, 1986). In 1979, however, Keen et. al. documented an association,
counter to expectation, of increased body mass index and glucose intolerance
with decreased energy intake and hypothesised that a "low energy
throughput state" may contribute to the pathogenesis of obesity and
abnormal glucose tolerance. Other studies have demonstrated abnormalities
of energy expenditure in the obese and Type II diabetic subjects in response
to intravenous (Ravussin et. al., 1983) and oral (Golay et. al., 1982) glucose
and it has been further suggested that these may predispose to failure of
weight loss and relapse of the obese state (Schutz et. al., 198^b).
Nevertheless, when the overweight Type II diabetic subject fails to
achieve adequate glycaemic control on dietary measures alone, treatment
with oral hypoglycaemic therapy is indicated.
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The biguanide derivative, metformin, is often considered to be the
drug of first choice in the management of these subjects as this agent has
been demonstrated to facilitate weight loss whereas the alternative
therapeutic option, sulphonylurea therapy, usually predisposes to weight
gain.
In 1968, Clarke and Duncan demonstrated in a prospective study
involving 77 obese Type II diabetic subjects previously inadequately
controlled on dietary restriction, a mean weight gain of 11.6 lb (5.3 kg) on
sulphonylurea therapy in contrast to a significant mean weight loss of 2.7 lb
(1.3 kg) on metformin during one year on each therapy (Fig. 4.1). Other
workers have confirmed these findings with metformin (Pedersen, 1965;
Mehotra and Young, 1967) and the other major biguanide derivative,
phenformin (Patel and Stowers, 1964; Mirsky and Schwartz, 1966).
Nine years following their original observations Clarke and Campbell
(1977) confirmed not only a similar pattern of weight loss and gain on
metformin and sulphonylurea but also demonstrated that metformin was
equally effective as chlorpropamide in achieving glycaemic control. Thus,
metformin has emerged as the treatment of choice of the obese Type II
diabetic subject who has failed to control on dietary measures alone.
Biguanides have also been demonstrated in a placebo controlled study to
induce a small change in weight in non-diabetic obese subjects (Munro et. al.,
1969).
Despite the widespread agreement of these workers on the attainment
of weight loss with metformin, opinions vary widely as to the mechanism
whereby this is achieved. Some workers have attributed the reduction in
weight to a diminution in energy intake as a result of the anorectic
properties of biguanide therapy (Patel and Stowers, 1964) whereas others
have failed to find such a relationship (Weller, 1965; Pedersen, 1965;
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Fig. 4.1. Mean weight change (lbs) during twelve months
treatment with chlorpropamide and with sulphonylurea
(n = 77).
Reproduced from Clarke and Duncan ( 1968) with the
permission of the Lancet.
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Mehotra and Young, 1967; Clarke and Duncan, 1968).
The other postulated mechanism of 'caloric sparing' by metformin is
that of induction of malabsorption. Although the biguanide derivatives have
been demonstrated to result in reduction of intestinal absorption of glucose
(Biro et. al., 1961; Czyzyk et. al., 1967), amino acids (Caspary and
Creutzfeld, 1973) and triglycerides (Curtis-Prior, 1982) in animal models and
vitamin B12 in man (Tomkin et. al., 1971) there is no conclusive evidence
that this can account for the therapeutic effect of metformin on weight
control in diabetic man.
Clarke and Duncan (1968) over 18 years ago suggested that "if
reduction in food intake is not the cause of obese diabetics tending to lose
rather than gain weight during biguanide therapy then the net increase in
retained calories must be disposed of by some catabolic non-tissue forming
metabolic process". Despite this, the hypothesis that metformin may act to
increase energy expenditure in these subjects has not been previously
investigated. The present study was therefore designed to investigate
whether alterations in energy expenditure could account for the differences
in weight gain reported during metformin and sulphonylurea therapy.
4.2. EXPERIMENTAL PROCEDURE
4.2.1. Protocol
The RMR and thermic responses to a mixed meal and noradrenaline
during treatment with metformin or a sulphonylurea derivative were
compared in nine Type II diabetic subjects in an open crossover study.
The nine subjects, acting as their own control, were studied initially
on their usual hypoglycaemic therapy. At recruitment three subjects were
taking metformin and six subjects sulphonylurea derivatives. Those subjects
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initially on sulphonylurea had their therapy changed to metformin 1500 mg
daily (Lipha Pharmaceuticals, Ltd.) in divided doses with meals, whereas
those subjects initially on metformin were changed to glipizide 5 mg daily
(Pfizer, Ltd.).
The alternative therapy was continued for 15 days and measurements
of energy expenditure were repeated on the 14th and 15th days following
changeover. All subjects maintained their prescribed diet during the study.
Subjects were alerted to the potential adverse reactions of
hypoglycaemia during sulphonylurea therapy and gastro-intestinal symptoms
during treatment with metformin and were instructed to report these
immediately.
4.2.2. Subjects
Nine Type II diabetic subjects, aged less than 55 years, who had been
treated with diet and oral hypoglycaemic therapy for at least three months
were recruited from Ninewells Hospital Diabetic Clinic between April and
December 1985. As the study involved infusion of noradrenaline, hypertensive
subjects (sitting blood pressure of greater than 140/90 mmHg) were excluded.
Concurrent medication with 8-blockers, sympathomimetic agents and
thyroxine, which may alter the RMR and thermic responses, contraindicated
recruitment to the study. All subjects had normal renal, hepatic and thyroid
function as estimated by measurement of plasma urea, creatinine, bilirubin,
alkaline phosphatase, alanine and aspartate amino transferases, thyroxine
and TSH concentrations. None of the subjects had evidence of complications
of diabetes mellitus using the criteria described in Section 3.2.1.1.
Those subjects not already familiar with home blood glucose
monitoring (BM Stix, Boehringer-Mannheim Ltd.) were instructed in this
technique. Routine blood testing was performed twice daily (fasting and
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2 hours following the largest meal of the day) during the two weeks prior to
study on their usual hypoglycaemic agent and also during the two week
period on alternative therapy. The age, sex, weight, body mass index, HbAj%
and oral hypoglycaemic therapy at recruitment of those subjects that
completed the study are shown in Table 4.1.
4.2.3. Body Weight
Body weight was measured prior to the measurement of RMR on first
study day, in light clothing without shoes, on each therapy.
4.2.4. Measurement of Energy Expenditure
Energy expenditure was measured using the indirect ventilated hood
calorimeter described in Section 2.1.2 and all subjects were familiarised with
the apparatus prior to study.
4.2.4.1. Resting Metabolic Rate
The resting metabolic rate was measured following an overnight fast
and prior to the measurement of the thermic effect of a meal or
noradrenaline on both metformin and sulphonylurea therapy, according to
the protocol described in Section 2.1.3. All measurements were performed
prior to the ingestion of the morning dose of the oral hypoglycaemic agent.
4.2.4.2. Thermic Response to the Meal
A similar liquid meal to that described previously (Section 2.1.5.1) was
given to each subject following the measurement of the RMR. The oral
hypoglycaemic agent under study was taken at the start of each meal.
Venous blood samples were withdrawn for analysis of glucose and insulin
concentrations at -5, 0, +30, +60, +90 and 120 minutes post ingestion and
SubjectAg(years)exW ight(kBodyM sIndex
(kg/m2)
141M102.632.0 244M121.137.9 346M66.622.3 452F73.827. 542F71.36 2 644F10 .735 8 748M87.52 .3 Mean45.3:F89.72 9
±SD3.74:320.45.6 Table4.1:Su jectdetailsofthosewhocomplet dstu yprotocol
HbAj%Duration
ofDiabetes(years)

























were collected and prepared in a similar manner to that described in Section
2.2.1.
4.2.4.3. Thermic Response to Noradrenaline
Noradrenaline was infused at a dose of 0.1 yg/kg IBW/min as
previously described (Section 2.1.5.2) after the measurement of the RMR and
prior to the morning dose of oral hypoglycaemic therapy. Venous blood
samples were obtained at -5, 0, +15, +30 and +45 minutes during infusion for
analysis of free fatty acids, glycerol, glucose and insulin concentrations.
4.2.5. Plasma Insulin
Plasma insulin was measured using a polyethylene glycol (PEG)
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assisted double antibody technique (Insulin ( I) KIT, Cambridge Medical
Diagnostic Inc.). The principle depends on the competition between insulin in
125the plasma and a fixed amount of radiolabeled ( I) insulin for a limited
number of binding sites on an antibody raised in guinea pigs against insulin.
The proportion of bound radiolabeled insulin varies inversely with the
concentration of unlabeled insulin in the plasma sample. Precipitation of
the antigen-antibody complexes is accomplished by a combination of goat
anti-guinea pig gamma globulin and PEG. This insoluble complex is
separated by centrifugation at 1500 G for 10 minutes. The quantity of
unlabeled antigen in an unknown sample is thus determined by comparing
the radioactivity of the precipitate after centrifugation with values
established using known standards (5-300 mU/1) in the same assay system.
The inter-assay C.V. was 8.4% and intra-assay 6.9%.
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4.3. RESULTS
4.3.1. Efficacy of Alternative Hypoglycaemic Therapy
4.3.1.1. Adverse Reactions
Two subjects failed to complete the study protocol due to adverse
reactions on alteration of therapy. One subject was withdrawn from the study
after 5 days of glipizide therapy as he complained of symptoms of headache
and sweating 2 to 3 hours following meals associated with BM Stix values of
between 2 to 4 mmol/1. Glipizide was therefore discontinued and he was
recommenced on dietary treatment alone.
Another subject developed abdominal cramps and watery diarrhoea
subsequent to changing to metformin therapy which persisted after 4 days of
therapy. Although this may have responded to reduction in the dosage of
metformin, he was withdrawn from the study and recommenced chlorprop¬
amide.
Of the remaining five subjects who changed from sulphonylurea to
metformin therapy, two (subjects Nos. 2 and 4) noted mild looseness of their
bowel motions which resolved spontaneously after 3 to 4 days without
alteration of the dosage of metformin.
4.3.1.2. Glycaemic Control
In the remaining 7 subjects who successfully completed the study
protocol, glycaemic control was similar on metformin and sulphonyulurea
therapy. This was estimated not only from the subjects' own records of home
glucose monitoring which ranged from 4 to 10 mmol/1 but also from the
fasting plasma glucose concentrations obtained prior to the meal and
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4.3.2. Body Weight
There was no significant change in body weight after 2 weeks on
alternative therapy (Table 4.3).
4.3.3. Resting Metabolic Rate
There was no significant change in RMR on metformin or sulphonylurea
therapy (Table 4.3) and this was statistically similar and closely correlated
(r = 0.96; p<.0001) with the predicted value based on age, sex and surface
area (3.20 ± 0.26 kJ/min).
4.3.4. Thermic Response to the Meal
The rise in metabolic rate in response to the mixed meal following
the administration of either metformin or sulphonylurea is illustrated in
Figure 4.2(a) and was similar on both drugs. There was no significant
difference in the accumulative thermic response to the meal over 2 hours on
either therapy (Table 4.3). The mean difference of +1.65 KJ had a t value of
0.506 and 95% confidence limits of -6.4 to +9.7 KJ.
4.3.5. Biochemical Response to the Meal , •
4.3.5.1. Glucose
The mean fasting plasma glucose prior to meal ingestion was similar
on metformin and sulphonylurea therapy. Although the mean plasma glucose
at 30, 60, 90 and 120 minutes following the meal was greater on metformin
this did not reach statistical significance (Fig. 4.3). However, when the
accumulative incremental rise of glucose over the 2 hour period was
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Fig. 4.2 Rise in metabolic rate following meal ingestion and during
noradrenaline infusion on metformin (•) and sulphonylurea (■)
therapy
(a) Meal ingestion
(b) Noradrenaline infusion. There were no significant
differences between groups. Mean + SEM.
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Fig. 4.3(a) PLASMA GLUCOSE RESPONSE TO MEAL
Minutes post ingestion
Fig. 4.3 Plasma glucose and insulin response to meal on sulphonylurea
( ■) and metformin (•) therapy
(a) Plasma glucose response




Plasma insulin concentrations were significantly greater at 60 and 90
minutes (Fig. 4.3) following meal ingestion as was the accumulative
incremental rise of insulin in response to the meal on sulphonylurea therapy
(Table 4.2).
4.3.6. Thermic Response to Noradrenaline
Noradrenaline infusion resulted in a significant rise in metabolic rate
in all subjects and the mean absolute (Fig. 4.2(b)) and accumulative
increment rises (Table 4.3) in response to the infusion were similar on both
therapies. The mean difference of 11 KJ had a t value of 0.95 and 95%
confidence limits -17 to +39 KJ.
4.3.7. Biochemical Response to Infused Noradrenaline
4.3.7.1. Glucose
Plasma glucose rose significantly on both therapies during noradrenaline
infusion (Fig. 4.4(a)). The accumulative incremental rise of glucose (Table
4.2) was however significantly greater on metformin.
4.3.7.2. Insulin
There was a biphasic response of plasma insulin to the continued
effects of fasting and noradrenaline infusion. After 15 minutes there was a
significant fall in plasma insulin on both metformin and sulphonylurea (Fig.
4.4(b)). During the subsequent 30 minutes plasma insulin concentrations
increased to that approaching the fasting value. The accumulative net fall in











kA Plasma glucose and insulin response to noradrenaline
infusion on metformin (•) and sulphonylurea (■) therap)
(a) Plasma glucose response
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Fig 4.5 Lipolytic response to noradrenaline infusion.
Metformin (• ); Sulphonylurea (■ ).
4.5 (a) Plasma non-esterifield fatty acids (NEFA)
during noradrenaline infusion.
4.5 (b) Plasma glycerol during noradrenaline infusion.
There were no significant differences between groups.
120
4.3.7.3. Glycerol and free fatty acids
Fasting plasma glycerol and free (non-esterified) fatty acid
concentrations were similar on metformin and sulphonylurea treatment as
were the lipolytic responses to infused noradrenaline (Fig. 4.5 and Table
4.2).
4.4. DISCUSSION
The resting metabolic rate and the increases in heat production
consequent to food and catecholamine stimulation can account for 80 to 90%
of total daily energy expenditure. Measurement of these parameters in Type
II diabetic subjects treated with metformin or a sulphonylurea under similar
conditions of glycaemic control failed to demonstrate any alteration of
energy expenditure on either therapy.
Thus it would appear that, at least in the short term, the weight loss
observed during metformin therapy and conversely the weight gain during
treatment with a sulphonylurea derivative (Clarke and Duncan, 1968) are not
facilitated by major changes in energy output. It is unlikely that the lack of
any consistent difference between metformin and sulphonylurea was due to
cross interference with the previous therapy or to an inadequate period of
therapy with the other. Metformin reaches a maximum plasma concentration
within 2 hours of dosage and has a plasma half life of 4 to 8 hours (Tucker
et. al., 1981). The sulphonylurea agents used in this study all reach peak
plasma concentrations within 2 hours of doage and as can be seen from
Figure 4.4 result in significant insulin release after minutes. Chlorpropamide
has the longest half life of the sulphonylurea agents at 35 hours (Martindale,
1982) but nevertheless there is no evidence to suggest that these drugs would
remain in the tissues 14 days after cessation of therapy in concentrations
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likely to interfere with the thermic responses on subsequent therapy.
One can argue, however, that as significant changes in body weight do
not occur until after several months of therapy with either drug (Clarke and
Duncan, 1968) changes in energy expenditure may not be demonstrable after
2 weeks of therapy. However, the study was deliberately designed to be of
sufficient duration to ensure therapeutic effect and yet avoid significant
alterations in body weight and fat free mass, as these changes per se would
have resulted in alteration of the RMR. Thus, if metformin therapy had
resulted in weight loss the resultant fall in the RMR secondary to the
reduction in fat free mass would confound clear interpretation of an effect
of metformin on energy expenditure.
By exclusion, therefore, alterations in available energy intake are
most likely to account for the considerable net weight change of 6.6 kg over
the 24 month period of study in Clarke and Duncan's original description
(1968). These workers calculated that this would represent an average
increase in daily energy intake in the region of 110 kcals. By comparison, it
has been demonstrated in Chapter III that alterations of energy expenditure
in Type I diabetic subjects of a similar magnitude (89 kcals/day) can also
result in a significant increase in weight (Section 3.3.2).
Assessment of daily energy intake was not carried out during this
study but it is interesting to note that even in this small group of subjects
one third of those subjects noted mild to moderate gastrointestinal symptoms
during metformin therapy which could result in the reduction of appetite or
absorption of nutrients. These symptoms, however, tended to be transient and
Clarke and Duncan (1968), who described a similar incidence of side effects,
failed to find a relationship between those patients who achieved weight loss
and those patients who had symptoms of anorexia.
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To detect a caloric deficit in the region of 100 kcal/day would require
a consistent accuracy of recording of at least 90-94% of the daily energy
input. In the free-living subject, studied outwith the confines of a metabolic
ward, even weighed daily diary recording of intake is unlikely to achieve an
accuracy of this degree and even if it approaches this, the methods involved
will result in significant alteration of eating behaviour which will negate the
object of the study (Garrow, 1978).
It has also been suggested, mainly from animal studies (see Section
4.1) that metformin may reduce available intake of the major nutrients via
diminished intestinal absorption (Section 4.1). It is not possible to comment
on the absorption of nutrients from the present study. The significantly
greater rise of plasma glucose following meal ingestion on metformin
therapy would not suggest inhibition of intestinal absorption of glucose but
the concurrent attenuation of the rise of plasma insulin compared to that on
sulphonylurea is probably the major factor influencing this difference.
The exaggerated insulin response to a meal and glucose on
sulphonylurea is well recognised (Abramson and Arky, 1967) and may further
tend to promote weight gain through increased glucose utilisation and
lipogenesis in the Type II diabetic subject on sulphonylurea.
The individual components of energy expenditure in the treated Type
II diabetic subject will now be considered with reference to the suggestion
that impaired glucose tolerance may act to predispose the diabetic subject
to weight gain due to blunted energy expenditure (Felig, 1984).
Up to 70% of total daily energy expenditure can be accounted for by
the RMR and therefore this component acts as one of the major
determinants of energy output in man (Garrow, 1985).
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The RMR of the Type II diabetic subjects studied was not significantly
different from that predicted for non-diabetic subjects based on age, sex and
surface area. Therefore this component does not act to limit energy
expenditure in the Type II diabetic subject. Conversely, the total 24 h
energy expenditure of an overweight individual will in fact be greater than
that of a sex and age matched lean individual due to the mathematical
relationship of the RMR to surface area (Boothby and Sandiford, 1929) or fat
free mass (Ravussin et. al., 1982) and the additional expenditure involved in
movement of the increased body mass.
The normal RMR of the Type II diabetic subject is in contrast to that
previously described in the poorly controlled diabetic Type 1 diabetic subject
(Section 3.3.4). Although elevation of the plasma glucose appeared to be a
major determinant of this abnormality in Type I diabetic subjects (Section
3.3.4) it is not possible to comment whether the normal RMR in the Type II
diabetics reflects the better degree of glycaemic control or a further
fundamental difference between Type I and Type II diabetes mellitus.
Recent data from Nair et. al. (1986) has addressed this problem and
contrasts with the present experience in that not only did the obese type II
diabetic subjects demonstrate a significantly raised RMR compared to
predicted but also those subjects with impaired glucose tolerance who were
not frankly diabetic. These differences may be partly accounted for by the
gross obesity of the subjects studied (BMI 38.2 ± 3.3 kg/m ) and the
"discontinuation of therapy for a period of one week" prior to study but it is
still surprising that those subjects with glucose intolerance (mean 2 hour 75
g glucose tolerance test glucose concentration of 9 mrnol/1) had a
significantly raised RMR if glycaemic control is one of the major factors in
determining the increase in RMR in diabetes mellitus (Section 3.3.3).
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As differences in the RMR between lean and obese subjects does not
reveal any evidence of decreased energy output in the obese state attention
has been focussed on dynamic aspects of energy expenditure such as the
responses to food and catecholamines.
The thermic response to the mixed constituent meal was unaltered in
the Type II diabetic subject whether on metformin or sulphonylurea therapy
and further, was similar to that observed in younger lean non-diabetic
subjects (72.2 ± 8.4 kJ/min; Table 3.6) and Type I diabetic subjects on
conventional therapy (73.6 ± 12.3 kJ/min; Table 3.6) and CSII (71.0 ± 12.1
kJ/min; Table 3.6).
This is in marked contrast to the reports of blunted thermic responses
to infused (Ravussin et. al., 1983) and oral (Golay et. al., 1982; Schutz et. ah,
1984b) glucose in obese Type II diabetics. The latter workers further
hypothesised that as this abnormality persisted despite weight loss it may
act as a factor predisposing to the relapse of the obese state. The
composition of the more physiological meal used in the present study
compared to large doses of infused and oral glucose has already been
discussed in Section 3.4.3 and may partly explain the conflicting evidence
but two other factors may be of importance. Firstly the Type II subjects
recruited for the previous studies were selected not only on the basis of
Type II diabetes mellitus but also had a family history of obesity and were
grossly obese with a %Ideal Body Weight in excess of 130%. Secondly, these
subjects were not receiving a carbohydrate restricted diet (maintenance diet
contained 230 to 300 g carbohydrate daily) and had not received oral
medication for at least 48 hours prior to study.
Although, therefore, it is not possible to cross compare these studies
with the present work it can be concluded that in Type II diabetic subjects
controlled with diet and oral hypoglycaemic agents, who were not selected
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on the basis of obesity, do not demonstrate an abnormality in the thermic
response to a mixed constituent liquid meal.
Finally, to a consideration of the thermic response to catecholamine
infusion in Type II diabetes. The thermic and lipolytic responses to
noradrenaline were also similar on metformin and sulphonylurea and to those
reported for younger lean, non diabetic subjects (27.1 ± 3.4 kJ/min; Table
3.6) and those recalculated from Finer et. al.(1985) (21.9 kJ/min) using a
similar noradrenaline infusion regimen.
This contrasts with the persistent blunting of the thermic responses to
infused noradrenaline in Type I diabetic subjects irrespective of the degree
of glycaemic control (Table 3.6) and obese subjects of similar age to the
current study before and after weight loss (Jung et. al., 1979). As these
abnormalities have also been demonstrated in the non-obese lactating
subject with apparent increased insulin sensitivity (Illingworth et. ah, 1986)
it would appear that abnormal glucose tolerance and the obese state are not
prerequisites of this abnormality. This suggests that some other factor or
factors unrelated to insulin responsiveness, and as yet unidentified,
modulates the physiological thermic response to infused catecholamines.
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Chapter V




In order to assess the histological, biochemical and functional
characteristics of brown adipose tissue in adult man, perirenal fat was
obtained from 31 subjects either at post mortem or during renal surgery.
Brown adipose tissue was demonstrable macroscopically in 16 out of
the 20 subjects (80%) in whom the total perinephric fat depot was obtained.
Histological studies confirmed the presence of multilocular adipocytes with
dense mitochondria associated with a rich vascular supply and sympathetic
innervation.
Measurement of GDP binding demonstrated the presence of uncoupling
protein, the prerequisite for brown adipose tissue thermogenesis, in
concentrations intermediate to that of the warm and cold adapted guinea
pig. Function of the uncoupling protein was demonstrated by fatty acid
stimulation and GDP inhibition of respiration in isolated mitochondria and
these data indicate some potential for thermogenesis in brown adipose tissue
in adult man.
However, calculation of the contribution of this tissue to the in vivo
response to noradrenaline, extrapolated from data of the tissue cytochrome c
oxidase activity and the in vitro response of isolated brown adipocytes to
noradrenaline, suggests that this tissue only accounts for 0.2% of the thermic
response to infused noradrenaline.
Thus although brown fat has been found to be quantitatively important
in animal studies, considerable caution must be exercised in extrapolating its
significance to adult man.
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5.1. INTRODUCTION
As reviewed in Chapter I, brown fat thermogenesis in small mammals
adapts to both temperature (Himms-Hagen, 1984) and dietary stimuli
(Rothwell and Stock, 1979) to produce heat for the maintenance of body
temperature in the former situation and to dissipate excess calories in the
latter.
In adult man there is evidence to support similar adaptive changes in
non-shivering thermogenesis (NST) occurring in response to cold (Joy, 1963)
and overfeeding (Sims, 1976). Presumptively, by analogy with animal models
and morphological extrapolation brown adipose tissue has been implicated as
the effector of NST although no direct role has been conclusively
demonstrated. Accordingly, defective brown adipose tissue thermogenesis in
obese adult man similar to that observed in some genetically obese rodents
has been speculated (Jung et. al., 1979).
However, as outlined in the preceding chapters, despite extensive
research on many aspects of energy balance the cumulative energetic
significance of blunted thermic responses in obese (Jung et. al., 1979; Shetty
et. al., 1981) Type I (Leslie et. al., 1986) and Type II (Golay et. al., 1982)
diabetic and lactating subjects (Illingworth et. al., 1986) remains a subject of
controversy. A major obstacle to the interpretation of these data obtained
during various physiological and pathological states is the lack of
understanding of the basic physiological mechanism or mechanisms involved
in the generation of these thermic responses in man.
The present study was therefore designed to firstly, identify
histologically and biochemically the presence of functional brown adipose
tissue in the adult. Secondly, to attempt to quantify the proportion of the
thermic response to infused noradrenaline that can be accounted for by heat
production from this tissue. Finally, from this data it was therefore hoped to
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be able to comment on whether abnormalities of this tissue can be




As discussed in Chapter I, perirenal fat was chosen as the site for
study as this is one of the major sites of brown adipose tissue in adult man
(Table 1.1) and is also accessible for study both at post mortem and in the
living subject during surgical procedures involving the kidney. None of the
subjects from whom tissue was obtained were obese (BMI less than 28.6) nor
known to suffer from diabetes mellitus.
5.2.1.1. Post-mortem tissue (samples 1-10; Table 5.1)
Post-mortem tissue was obtained from cadavers, less than 18 h after
death who had died suddenly, by dissection of the total perinephric fat from
one kidney. The specimens were transported to the laboratory in an ice cold
solution containing 250 mmol/1 sucrose, 10 mmol/1 TES (2 [2-hydroxy-l,
l-bis(hydroxymethyl)ethyl]-aminoethane sulphonic acid), 1 mmol/1 EDTA at
pH 7.2.
Macroscopic examination of the major fat depots for the presence of
brown areas was performed in the post mortem subjects (subjects nos. 2, 3
and 4). Abdominal wall, anterior and posterior thigh, interscapular and
omental adipose tissue and the fat depots associated with the abdominal and
thoracic aorta, internal and external carotid arteries as well as the
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5.2.1.2. Per-operative tissue (Table 5.1)
Tissue was obtained during surgical procedures involving the kidney
either during nephrectomy when the total perinephric fat was obtained
(subject nos. 22-31; Table 5.1) or during procedures when the retroperitoneal
area was exposed (subject nos. 11-21; Table 5.1). These samples consisted of
small biopsies (1-4 g net weight) selected by the surgeon on the basis of ease
of attainment.
Tissue for mitochondrial preparation was transported to the laboratory
in a similar medium to that for post mortem tissue (Section 5.2.1.1.). When
isolated adipocytes were to be prepared, this was substituted for by "cell
isolation medium", containing 110 mmol/1 NaCl, 5 mmol/1 KCL, 5 mmol/1
NaT^PO^, 1.5 mmol/1 KH^PO^, 5 mmol/1 NaHCO^ 10 mmol/1 pyruvate, 10
mmol/1 TES, 1.4 mmol/1 Mg SO^, 1.5 mmol/1 CaC^j 10 mmol/1 glucose, 10
mmol/1 fructose, 64 ymnol/1 albumin at pH 7.4 and 37°C.
5.2.2. Anatomy
5.2.2.1. Macroscopic appearance
Tissue was examined macroscopically in theatre prior to transport for
the presence of brown discolouration which is typical of thermoregulatory
active brown adipose tissue in animals, and samples taken for histological
examination.
5.2.2.2. Light microscopy
Material for light microscopy was fixed in 10% formol saline prior to
processing as follows: 1) paraffin embedding and sectioning at 10 pm for
haemotoxylin and eosin (H and E) staining or for silver impregnation by the
Holmes method and 2) freeze microtomy at 15 pm for the application of oil
Red O method for lipid demonstration.
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Material for fluorescence microscopy was frozen by dry ice onto
chucks and transported by train to Professor J.D. Lever, University College,
Cardiff for the demonstration of catecholamines. On receipt, cryostat
sections 12-15 ym thick were cut at -30°C, thawed directly onto glass slides
and processed by a modification of the sucrose-potassium phosphate-glyoxylic
acid (SPG) technique of de la Torre and Surgeon (1976).
5.2.2.3. Electron microscopy
Material for electron microscopy was fixed in ice-cold cacodylate-
buffered 3% glutaldehyde for ^ hours prior to an overnight buffer wash and
subsequent post fixation in 1% buffered osmium tetroxide before processing
to araldite. Fine sections (600-900 A thick) were stained with uranyl acetate
and lead citrate prior to examination by Professor J.D. Lever (Cardiff) and
Dr D. Hopwood (Dundee).
5.2.3. Tissue Preparation
Tissue for mitochondrial preparation and adipocyte isolation was
rapidly dissected free of blood vessels and connective tissue with fine
scissors. In the majority of samples dark coloured foci were distinguishable
amongst white coloured fat, weighed and processed separately. In those cases
where delineation between light and dark areas was not possible the
undifferentiated sample was pooled for subsequent analysis. Cleaned tissue
was then minced finely with scissors.
5.2.3.1. Mitochondrial preparation
Tissue for mitochondrial preparation was homogenised in six times its
volume of 250 mmol/1 sucrose, 10 mmol/1 TES (sodium salt), 1 mmol EDTA at
pH 7.2. The homogenate was subsequently filtered through 200 yM nylon
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mesh gauze and centrifuged at 12,000 r.p.m. for ten minutes. The
supernatant was discarded and the pellet suspended in a medium consisting
of 230 mmol/1 sucrose, 120 mmol/1 TES (sodium salt), 1 mmol/ EDTA and 61
ymol/1 bovine serum albumin at pH 7.2. This medium was used for all
subsequent steps until the final spin. A low spin speed at 3,500 r.p.m. was
conducted for ten minutes in order to pellet red blood cells. The supernatant
was then centrifuged twice at 8500 r.p.m. for ten minutes. The final spin and
resuspension was made in 100 mmol/1 KCL, 5 mmol/1 TES at pH 7.0.
5.2.3.2. Adipocyte preparation
The minced tissue was pre-equilibrated at 37°C with 95% and 5%
CC>2 in cell isolation medium (Section 5.2.1.2.) and incubated in a water bath
for 15 minutes. Collagenase (2 mg/ml) and Ca++ ions (1.5 mmol/1) were then
added for 15 minutes. The tissue was then filtered through 200 yM mesh
nylon sieve. The cells were then suspended in cell isolation medium and
washed twice at 300 g max for 3 minutes. After the final wash cells were
counted in an improved Neurbauer haemocytometer.
5.2.1. Protein Determination
Mitochondrial protein was determined by the biuret method using
bovine serum albumin as the standard.
5.2.5. Cytochrome c Oxidase Activity
Cytochrome c oxidase is the terminal enzyme of the respiratory chain
and therefore provides an index of mitochondrial density. Assay of the
enzyme in brown adipose tissue immediately, and 18 h after death in guinea
pigs demonstrated stability of the enzyme in post mortem material (D.G.
Nicholls, personal communication). Huttunen et. al. (1981) have also
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confirmed the stability of this enzyme up to 5 days post mortem in human
pericardial fat.
50 to 100 mg of dark, light or undifferentiated tissue was homogenised
in a phosphate buffered medium containing 0.5% lubrol and the enzymic
activity determined polarographically at 37°C according to the method of
Rafael (1983). Calculated values were expressed as ymoles O/min/g tissue
from homogenised tissue samples and as ymoles O/min/mg mitochondrial
preparations from light and dark areas.
From specimens in which the total perinephric fat depot was obtained
the total capacity of the enzyme in the fat surrounding the kidney was
calculated from the specific activity of each area and the percentage of
light and dark areas in the total weighed sample. Biopsy samples were not
quantifiable in terms of total perirenal capacity.
5.2.6. Mitochondrial Respiratory and Membrane Potential Measurements
A thermostatically controlled perspex chamber was fitted with a
Clarke oxygen electrode and tetraphenyl phosphonium (TPP) sensitive
electrode with remote KCL reference, allowed a simultaneous monitoring of
respiration and membrane potential (Locke et. al., 1982). Mitochondria (0.3
mg/ml) were incubated in a medium containing 50 mmol/1 KCL, 10 mmol/1
TES, 2 mmol/I EGTA, 5 mmol/1 phosphate (sodium salt), 10 mmol/1 pyruvate,
6 mmol/1 malate, 10 mmol/1 sn-glycerol-3-phosphate, 2 yg/ml oligomycin, 5
ymol/1 TPP and 16 ymol/1 albumin at pH 7.0, 30°C.
To demonstrate respiratory control successive additions of 64 ymol/1
bovine serum albumin, 3 mmol/1 GDP and 2 aliquots of palmitate to create a
final fatty acid to albumin molar ratio of 1:1 and 2:1 were made (Fig. 5.6).
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5.2.7. Mitochondrial GDP Binding
The mitochondrial complement of uncoupling protein can be
determined by a purine nucleotide binding asay. The tritiated analogue of
guanosine 5' diphosphate (GDP) was employed as it has high affinity for the
nucleotide binding site of 32D uncoupling protein and its exclusion from the
mitochondrial matrix (Nicholls, 1976).
Mitochondria (0.3 mg/ml) were incubated at 30°C pH 7.0 in 700 yl of
nucleotide binding medium containing 100 mmol/1 acetate (potassium salt), 5
mmol/1 TES, 16 ymol/1 albumin, 1.3 ymol/1 rotenone, 10 ymol/1 (^H) GDP (10
yCi/ml) and 0.3 yCi/ml (^C)-sucrose. Binding was determined at a single 10
ymol/1 GDP concentration (Rial et. al., 1983).
5.2.8. Calculation of estimated in vivo contribution of brown adipose tissue
to noradrenaline stimulation.
5.2.8.1. In vitro response to noradrenaline
Ideally, in order to estimate the contribution that brown adipose tissue could
make to noradrenaline stimulated thermogenesis, isolated adipocytes should
be prepared in vitro under conditions equivalent to in vivo responsiveness.
The increase in respiration of these cells on addition of noradrenaline could
then be expressed as a percentage of the mitochondrial density (cytochrome
c oxidase activity). From a knowledge of total cytochrome c oxidase activity
of the tissue, the in vivo response of that tissue can be extrapolated.
Isolated brown adipocytes from human subjects were prepared as described
(Section 5.2.3.2.) in parallel with those from the dorsal fat pad of warm
adapted and cold adapted guinea pigs of either sex maintained at either
28-31°C (warm adapted) or k-7°C (cold adapted) for at least 2
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weeks. Basal and stimulated respiration were measured in the oxygen
electrode. Maximal stimulation was achieved with the addition of
noradrenaline to a final concentration of 10 ymol/1. A sample calculation
and the assumptions made in this calculation are discussed in the results
section (5.3.7.1).
5.2.8.2. In vivo response to noradrenaline
The eight non-diabetic subjects described in Chapter III (Section
3.2.1.2) who were infused with 0.1 pg/kg IBW/min of noradrenaline for 't5
minutes (Section 2.1.5.2) were used to assess this parameter. The maximal hi
vivo response was taken as the difference between the mean basal oxygen
consumption and that obtained during the final 15 minutes of the
noradrenaline infusion and expressed in ml O^/min.
5.3. RESULTS
5.3.1. Anatomy
Macroscopic examination of the major fat depots for the presence of
brown adipose tissue was performed on three post-mortem subjects (Nos. 2, 3,
ty). Apart from the perirenal area in all subjects and a small deposit around
the abdominal aorta at the origin of the renal arteries in subject no. 2,
macroscopic and histological brown adipose tissue was not demonstrable.
Those areas sampled consisted of unilocular cells and in all cases apart from
the perirenal site, it was not possible to prepare a sufficient mitochondrial
pellet from less than 6 g of tissue indicative of a low mitochondrial density
and metabolic activity.
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Thus from this small pilot study, which confirmed the data of Heaton
et. al. (1972) subsequent attention was focussed on perirenal adipose tissue.
5.3.1.1. Macroscopic Appearance (Table 5.1, Fig. 5.1)
Macroscopically areas of brown colouration were demonstrated in 16
out of the 20 samples (80%) when the total perinephric fat depot (post
mortem and nephrectomy tissue) was obtained. This could be formally
dissected, quantified and studied separately in 13 of these samples.
Biopsy samples usually weighing less than b g yielded a similar
percentage of positive identifications (8 out of 11 samples) but was more
difficult to quantify formally (5 out of 11 samples).
The distribution of the brown fat varied from well demarcated areas
(Fig. 5.1) to small "islets" less than 5 mm in diameter distributed uniformly
through the fat which made separate dissection impossible (6 out of 31
samples).
Deposits could be found with equal occurrence at the anterior,
posterior, inferior and superior poles of the kidney as well as the hilum and
periadrenal area.
All samples received from subjects under the age of 50 years where
the total perinephric fat was obtained displayed localised areas of distinct
brown colouration. Three positive identifications (one in a patient aged 69
years) out of six were recorded from older patients.
The net weight of dissected brown fat varied from detectable to 2^ g.
This latter specimen was obtained from a 51 year old subject who had a
large hypernephroma with pericapsular extension of tumour. Histological
examination of the brown discoloured areas revealed these contained
multilocular adipocytes and not tumour cells.
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10 cm.
Fig. 5.1. Macroscopic appearance of perinephric fat from subject
no. 5 (Table 5.1) obtained at post mortem. Clear demarcation
is seen between the brown adipose tissue (upper arrow) and
white adipose tissue (lower arrow).
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5.3.1.2. Phaeochromocytoma (Subjects 17 and 18)
In the two subjects diagnosed with phaeochromocytoma both had a
greater than 2 year history of poorly controlled hypertension.
Subject No. 17 had raised urinary metanephrine excretion on three 24
hour urine specimens and a resting supine plasma noradrenaline concentration
of 31.2 nmol/1 (normal resting supine range up to 4 nmol/1) and resting
supine adrenaline concentration of 5.2 nmol/1 (reference range up 1.5
nmol/1). Subject No. 18 had a peripheral venous plasma noradrenaline
concentration of 350 nmol/1 and adrenal venous blood obtained peri-operatively
had a concentration of 794 nmol/l. In neither subject was a brown fat tissue
mass or hibernoma (Section 1.5.2.1) visualised at operation. Periadrenal fat
demonstrated scattered foci of brown tissue in subject no. 18 and was
undetectable in subject no. 17.
5.3.1.3. Light Microscopy
Thermogenically active brown adipocytes in the small mammal can be
identified under the light microscope by the presence of granular
multilocular adipocytes. The typical appearance of multilocular brown
adipocytes adjacent to unilocular adipocytes obtained from subject no. 4 is
shown in Fig. 5.2. The areas of multilocularity are associated with a rich
vascular capillary supply whereas those areas where unilocular cells
predominate appear to have a sparse vascular supply. These unilocular
adipocytes are typical of white adipocytes but equally well may represent
quiescent brown fat cells as suggested by the presence of GDP binding
(uncoupling protein) in macroscopically light areas. After silver
impregnation an abundant vasomotor nerve plexus was discernible on the
walls of small arteries and nerves were traced in parenchymal distribution
between multilocular adipocytes. Within these plexuses were putative
l'f I
Fig. 5.2 Paraffin section of perinephric adipose tissue obtained from
subject no. 4 stained with haemotoxylin and eosin X 920. To the
left of the photograph is seen the typical multilocular
appearance of brown adipocytes in contrast to the unilocular
white adipocytes on the right.
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catecholaminergic nerve fibres characterised by fluorescence in SPG
preparations (Fig. 5.3).
5.3.1.4. Electron Microscopy
Fig. 5.4 shows an electron micrograph representative of perirenal
'dark' tissue. The large spherical nucleus, with prominent nucleoli, the
multilocular fat droplets and numerous mitochondria with involuted dense
cristae are demonstrated.
Fig. 5.5 shows an unmyelinated axon bundle in an intercellular space
between brown adipocytes. Terminal features were observed in many of these
nerves and included the presence of 800-1000 A diameter dense cored
vesicles as well as a number of 400-600 A diameter clear vesicles.
5.3.2. Cytochrome c Oxidase Activity
Cytochrome c oxidase activity was measured in the tissue homogenates
and respective mitochondria in 12 subjects (Table 5.2) and was consistently
less than comparable data obtained from warm and cold adapted guinea pigs.
From these parameters the complement of mitochondrial protein per gramme
of tissue (a more accurate estimate of mitochondrial density) can be
estimated and this demonstrates two features.
Firstly, dark areas are more abdundant in their complement of protein
than are light areas indicating greater metabolic activity and, secondly, only
in one subject (subject no. 23) did the protein complement approach that of
the warm adapted guinea pig.
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Fig. 5.3 Fluorescence micrograph of glyoxylic acid-treated
human perirenal tissue from 39 year old subject.
Scale base 10 ym (X 750). Note beaded fluorescent
axons on the walls of an artery (light arrows) and
in parenchymal distribution (heavy arrows).
Also note widespread distribution of lipofuchsin granules
(circle) within adipocytes.
Fig. 5A Electron micrograph (X 12,090) of a cell from a dark area of
perinephric fat from subject no. 26 showing numerous dense
mitochondria and multilocular fat droplets.
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Fig. 5.5. Electron micrograph of brown adipose tissue obtained from
subject no. 29.
A Schwann axon bundle in an intercellular space between
brown adipocytes. The bundle contains axons (heavy arrows)
exhibiting terminal features: large diameter (800-1000 A) dense-
cored vesicles (light arrows) and small diameter (400-600 A)
clear vesicles (arrowheads).
BA: peripheral cytoplasm of brown adipocytes
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5.3.3. Uncoupling Protein
Mitochondrial density reflects non specifically the metabolic activity
of the tissue under study whereas the presence of uncoupling protein is
unique to brown adipose tissue mitochondria and thus indicative of the
unique capacity for thermogenesis.
Values for 10 ymol GDP binding are shown in Table 5.3. The range of
all the human values both from light and dark areas lies midway between
that obtained from warm and cold adapted guinea pigs indicating that the
amount of uncoupling protein present is equivalent to that found in a
partially cold adapted animal. In four out of the five subjects in whom
macroscopic separation of light and dark areas for study were possible there
was a tendency for a greater degree of GDP binding indicative of increased
concentration of uncoupling protein in the dark areas. However, the results
also demonstrate the presence of significant GDP binding in macroscopically
"light" coloured areas demonstrating that active brown adipose tissue cannot
be identified by visual inspection alone.
The presence of uncoupling protein would be of limited consequence if
it were not functional i.e. capable of uncoupling respiration from oxidative
phosphorylation in the brown adipocyte. As discussed earlier (Section 1.3.3.3)
this protein confers on animal brown fat mitochondria a system of regulating
proton conductance which is inhibited by purine nucleotide binding and
activated by fatty acid. Hence the bioenergetic characteristics of the human
mitochondria were investigated under the influence of these proton
conductance regulators.
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10 pM GDP Binding
nmol/mg protein
Age (yrs) Subject No. Light Undifferentiated Dark
9 1 0.165 - 0.174
11 23 0.140 - 0.150
15 25 0.058 - 0.125
19 24 0.082 - 0.298
19 2 - 0.160 -
21 3 - 0.120 -
30 5 - 0.378 -
34 28 0.210 - 0.160
WA-Guinea pig 0.572
CA-Guinea pig 0.056
Table 5.3: Mitochondrial GDP binding: A comparison of human brown
adipose mitochondria with warm adapted (WA) and cold
adapted (CA) guinea pigs. Subject no. refers to Table 5.1.
Undifferentiated refers to experiments in which pooled
mitochondria from light and dark areas were studied.
149
5.3.4. Bioenergetic Properties of the Mitochondria
Fig. 5.6 and Table 5.4 illustrate the respiratory and membrane
potential measurements of mitochondria prepared from subject no. 14. The
low basal membrane potential and high basal rate of respiration is indicative
of the uncoupling of oxidative phosphorylation. The addition of albumin (Fig.
5.6), which binds fatty acids, thus resulted in an increase in membrane
potential and slight inhibition of respiration measured by a decrease in
slope. The addition of GDP resulted in a striking rise of membrane potential
and 66% inhibition of respiration indicative of purine nucleotide binding
preventing the dissipation of the proton electrochemical potential by the
uncoupling protein.
The subsequent addition of fatty acid in the form of palmitate
overrides this inhibition resulting in a decrease in membrane potential and
increase in respiration. This is attributable to the unmasking of the
uncoupling protein proton shunt, mimicking the respiratory control seen in
the warm and cold adapted guinea pig.
Table 5.4 also demonstrates that the basal respiratory rate and
membrane potential of human brown adipose tissue mitochondria is
intermediate to that of the warm and cold adapted guinea pig and provides
further evidence for the partially cold adapted state of adult man.
Thus far, the presence of functional uncoupling protein has been
demonstrated in human perirenal fat mitochondria. However, before human
brown adipose tissue can be implicated in regulatory thermogenesis it is
necessary to demonstrate uncoupling at the cellular level by the functional
presence of B-adrenoceptors capable of activating the sequence of events
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guinea pigs guinea pigs
Respiration
(nmol 'O'/min/mg protein)
Control 149 258 537
+ GDP 50 93 35
+ GDP + palmitate 73 159 132
Membrane Potential
(mV/mg protein)
Control 209 188 125
+ GDP 222 214 228
+ GDP + palmitate 211 188 203
Table 5.4: Bioenergetic properties of mitochondria prepared from human
perinephric fat (subject no. 14) and from the dorsal brown fat
pad of warm adapted and cold adapted guinea pigs. Respiration
and membrane potentials of subject no. 14 are illustrated in
Fig. 5.6 from which these data were derived.
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5.3.6. Thermogenesis in isolated human brown adipocytes
The preparation of isolated brown adipocytes was attempted on
several occasions but great difficulty was encountered in isolating functional
intact cells using the same protocol for guinea pig adipocytes. This was
mainly due to the comparatively small volume of tissue available, the low
adipocyte yield following collagenase digestion and washing and the
tendency for the human cells to lyse.
However, isolated adipocytes were successfully prepared from one
subject (no. 13), a 3 year old male and these were stimulated with
noradrenaline as described in Section 5.2.8.1.
Fig. 5.7 compares the catecholamine response of brown adipocytes
prepared from warm and cold adapted guinea pigs with those obtained from
this subject.
The addition of noradrenaline resulted in a four fold increment of the
basal respiration of human brown fat cells. This compares to a six fold
stimulation observed in the adipocytes of a warm adapted guinea pig and a
13 fold stimulation in those of a cold adapted animal. Therefore under
maximal noradrenaline stimulation the respiratory capacity of the human
brown adipocytes from this single subject approaches only 40% of the rates
monitored for warm adapted guinea pig cells. However, these cells were
capable of expressing a greater percentage of their cytochrome oxidase
activity under noradrenaline stimulation (Fig. 5.7) and this probably reflects
the lower mitochondrial complement of the human adipocyte which
nonetheless contain a greater amount of uncoupling protein per mitochondrion
(Section 5.3.2 and 5.3.3).
When this increase in respiration is expressed as a percentage of the
cytochrome oxidase activity the human cells demonstrate a value of 7% once





Fig. 5.7 Noradrenaline sensitivity of human brown fat cells (H-cells)
prepared from subject no. 13 and comparison with the response of
brown adipocytes from thermoneutral (T-cells) and cold adapted
(C-cells) guinea pigs. Respiration was measured in oxygen
electrode as described in Section 5.2.6. NA = addition of 10 ymol/1
noradrenaline. Basal and stimulated respiratory rates are shown
against the traces in nmol'O'/min/lO^ cells.
NA
^ - noradrenaline induced stimulation of respiration
COX expressed as a percentage of the cytochrome (oxidase
activity (COX) of each preparation.
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(15%) guinea pig.
5.3.7. Total Tissue Respiratory Capacity in Response to Noradrenaline
5.3.7.1. In vitro
From the GDP binding studies, human brown adipocytes appear to be
in a partially cold adapted state - the value of GDP binding lying
intermediate between that of the warm and cold adapted guinea pig (Section
5.3.3). As discussed above (Section 5.3.6) the percentage cytochrome oxidase
activity expressed subsequent to noradrenaline stimulation lies in this
intermediate range - the value from our single subject being 7%. Thus it can
be assumed from these two independent assessments that at most 7% of the
cytochrome oxidase activity would be expressed during stimulation. Using
this assumption and a knowledge of the cytochrome oxidase activity and the
total weight of perinephric fat surrounding one kidney the total respiratory
capacity of this tissue can be calculated. A sample calculation is illustrated
below for subject no. 2.
1. Total weight of perirenal fat = 71.0 g
Weight of light area = 58.9 g
Weight of dark area = 12.1 g
2. Cytochrome C oxidase activity (Cox/g)
Light area = 0.13 pmol 0/min/g
Dark area = 1.70 ymol 0/min/g
156
3. Cytochrome C oxidase activity/kidney
activity = (wt x Cox/g) light area +
(wt x Cox/g) dark area
= (58.9 x 0.13) + 12.1 x 1.70)
= 28.2 ymol 0/min/kidney
4. Respiratory capacity induced by noradrenaline/2 kidneys
= 7.0% of 28.2 ymol/mm/kidney
= 2.0 ymol 0/min/kidney
= 4.0 ymol/0/min/kidney
5. Conversion of ymol 0 to yl 0^
1 ymol of O2 occupies 22.4 yl at S.T.P.
1 ymol pf C^/min/depot = 11.4 x 4
= 44.8 yl 02/min/depot.
This calculation overestimates the values for two reasons. Firstly light
areas with their lower GDP binding and mitochondrial complement will
express a lower percentage of cytochrome oxidase activity than 7% which is
that extrapolated for dark areas. This figure only applies to the 12.1 g of
dark tissue - a lower value would be obtained by the remaining 58.9 g in this
example. Secondly the value of 7% is obtained from a 3 year old child whose




In the eight normal fasting subjects prior to noradrenaline infusion
(Section 3.2.1.2) the basal oxygen consumption measured by indirect
calorimetry ranged from 173 ± 219 ml/min. During the final 15 minute
period of the 45 minute noradrenaline infusion at a rate of 0.1 yg/kg
IBW/minute, this rose by 14 to 49 ml/min with a median rise of 31 ml/min.
5.3.8. Comparison of the in vitro and in vivo Responses
The value of a rise in oxygen consumption of 31 ml/min in vivo in
response to noradrenaline infusion which at most would achieve a plasma
-8
noradrenaline concentration of 10 M compares to the mean estimated
contribution of total perinephric adipose tissue of 30 yl following hi
vitro maximal stimulation at a noradrenaline concentration of 10(Table
5.5). Thus using this method of calculation less than 0.1% of the thermogenic
response to infused noradrenaline is accounted for by this tissue. Even if the
best response - 96 yl O^/rnin in subject no. 1 is considered and these cells
were in a maximally cold adapted state and expressed 15% of the activity
during noradrenaline stimulation this value would still only be in the order
of 164 yl 02/min - less than 1%.
5.4. DISCUSSION
The present study has considerably extended the current knowledge of
brown adipose tissue activity in man.
Brown adipose tissue was identified in the perinephric adipose tissue
of most adult subjects below, but less frequently above the age of 50 years.
This is a similar pattern to that described by Heaton (1972) who consistently
demonstrated multilocular adipocytes in the perirenal fat of subjects under
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the age of 20 years, but only in 60-80% of subjects aged 21 to 60 years.
Light and electron microscopy demonstrated the presence of typical
multilocular adipocytes with a high mitochondrial complement and for the
first time catecholaminergic innervation, which has previously only been
assumed, has been demonstrated in this tissue. Although the general trend
was of a diminution of cytochrome c oxidase activity and GDP binding
(indicative of the thermogenic capacity) with increasing age, there was no
significant correlation between these variables in the small sample tested.
In all samples tested the presence of uncoupling protein was
demonstrated by GDP binding. The values ranged from 0.378 nmol/mg
protein to 0.082 nmol/mg protein. Recently Lean et. al (1986) using a solid
phase radioimmunoassay (employing a specific rabbit anti-human uncoupling
protein anti-serum) measured similar concentrations of uncoupling protein in
perirenal and axillary adipose tissue in infants, children and adults. The
range of values obtained from 17 adults aged 18 to 86 years was 30 yg/mg
mitochondrial protein (0.468 nmol/mg) in a 24 year old subject to <0.8 yg/mg
(0.125 nmol/mg) - the lower limit of their assay. Although axillary fat
tended to have a higher concentration of uncoupling protein than perirenal
adipose tissue, the highest value in normal subjects was obtained from
perirenal tissue.
The work of Huttunen et. al. (1981) comparing the cytochrome c
oxidase activity of brown adipose tissue in 7 indoor and outdoor workers
which suggested increased activity of this enzyme in the latter group was
interpreted as evidence of regulatory cold adaptation in man. However the
cytochrome c oxidase activity of these subjects (0.047 to 0.025 ymol
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02/min/g tissue) falls well below the range of cytochrome c oxidase activity
obtained in the present study (10.0 to 0.1 ymol 0/min/g tissue). This probably
reflects differences in the method and delay of assay of the tissue but
nonetheless demonstrates the hazards of extrapolating from a small number
of subjects and inadequate control group.
The other major stimulus to brown adipose tissue metabolism that has
been examined in man is that of catecholamines. These can be considered in
two groups. Firstly, those studies in which the effects of the catecholamine
secreting tumour phaeochromocytoma on brown adipose tissue activity have
been examined, and secondly studies on the effects of sympathomimetic
agents such as ephedrine and noradrenaline on thermogenesis from this
tissue.
The association of "hibernomas" or "brown fat tumours" with
phaeochromocytoma has already been discussed (Section 1.5.2.1) but the
paucity of case reports suggests that this is an unusual finding. In the two
cases presented in this study there was no evidence of these discrete,
vascular brown fat deposits at laparotomy.
Ricquier et. al. (1982), using the same assay system employed in the
present study, measured the cytochrome c oxidase activity in "dark"
perirenal and periadrenal adipose tissue stained from two subjects with
phaeochromocytoma, and compared this to white adipose tissue obtained
from the omentum in the same subjects and also perirenal adipose tissue
from one subject without phaeochromocytoma. As in the present study, they
found cytochrome c oxidase activity and mitochondrial protein was greater
in dark areas compared to light areas. Comparison with 'control' white
adipose tissue suggested greater cytochrome c oxidase activity in adipose
tissue from patients with phaeochromocytoma but the maximum value from
peri-tumoural fat (0.37 ymol 0/min/g tissue) falls within the range obtained
in subjects without phaeochromocytoma in the present study (0.09 - 9.7 ymol
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O/min/g tissue). This group had similar difficulties to ourselves in obtaining
sufficient mitochrondrial yields from the small amounts of tissue available
at operation and only in one subject out of three was there a sufficient yield
to perform a GDP binding assay. The value obtained from this subject, using
a similar assay, was 0.21 nmol/mg protein which again falls within the range
of GDP binding obtained from subjects without phaeochromocytoma in the
present study (0.058 - 0.378 nmol/mg protein).
Recently, Lean et. al. (1986), using the radioimmunoassay method,
have demonstrated higher concentrations of uncoupling protein in three
subjects with phaeochromocytoma (40 year old female, 24 yg/mg (0.375
nmol/mg); 21 year old male, 50 yg/mg (0.781 nmol/mg) and a 22 year old
female, 26 yg/mg (0.406 nmol/mg). However, two subjects without
phaeochromocytoma in this study had concentrations of uncoupling protein
of 25 and 30 yg/mg respectively. There is still not enough information in the
literature to comment categorically, firstly whether these concentrations of
uncoupling protein are significantly raised and secondly if they are the
result of chronic noradrenaline stimulation. Thus, although noradrenaline
appears to be the major factor controlling the concentration of uncoupling
protein in rats (Mory et. al., 1984) this remains to be conclusively
demonstrated in man.
The function in vitro of isolated human brown adipose tissue
mitochondria and adipocytes in response to physiological stimulators
(non-esterified fatty acids and noradrenaline) and inhibitors (GDP) has not
been previously reported and confirms for the first time that the major
assumption of equating the presence of uncoupling protein with a potential
for thermogenesis in adult man is in fact correct.
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The major question posed by this study was the contribution this tissue
could make to the in vivo thermogenic response to noradrenaline as without
an estimate of the magnitude of this parameter, comparison with results
from animal models and extrapolation from histological and biochemical
evidence for the presence of brown adipose tissue in man is of limited value.
The inaccessibility of this tissue for study in vivo has proved a major
problem in answering this fundamental question and only one other study to
date has attempted this estimation (Astrup et. al., 1985b).
Fig. 5.8 illustrates the contribution of brown adipose tissue to in vivo
sympathetic thermogenesis from the data of the present study and those of
Astrup et. al. (1985b) in man with those obtained from the rat. This
comparison demonstrates from the results of these two studies the minor
importance of this tissue in sympathetic induced thermogenesis in man.
Astrup et. al. (1985b) tackled the problem of estimating the in vivo
thermogenic response of brown adipose tissue to sympathetic stimulation in
man using a totally independent method by measuring the increase in
oxygen consumption following the ingestion of 1 mg/kg of the sympatho¬
mimetic agent, ephedrine, in normal subjects.
Perirenal brown adipose tissue (BAT) thermogenesis was calculated
from the formula:
BAT Thermogenesis = (Tj - T ) X BAT Blood Flow x 3.68 (J/min)100 g)
where T^ = local BAT temperature (°C)
Tc - core temperature (°C)
The blood flow in perirenal adipose tissue was measured by a xenon
clearance technique and local brown adipose tissue temperature by a flexible
thermoprobe inserted in the perirenal tissue under ultrasound guidance. The
mean peak percentage rise in oxygen consumption following ephedrine


















Fig. 5.8 The contribution of brown adipose tissue (BAT) and other tissues
(non BAT) to noradrenaline induced thermogenesis in cold
acclimatised (CA), warm acclimatised (WA), normal rats and adult
man. The calculations are based on the results of Foster and
Frydman (1978a), Rothwell and Stock (1979), Astrup et. al.
(1985b) and the present data (Section 5.3.8)
Reproduced with permission from Astrup (1986)
significant rise in brown adipose thermogenesis. The fifth subject demonstrated
an increase in oxygen consumption of 80 yl C^/min per 10 g of tissue - in the
same order of magnitude as the total in vivo contribution of perirenal fat to
the increase in oxygen consumption in the present study (range ^ - 96 y 1
02/min). Thus the only two assessments to date of the thermogenic activity
of brown adipose tissue to sympathetic stimulation in living man have
independently assessed the contribution of this tissue to the total response
to be in the region of less than 1%.
Can these results be explained by an underestimation of the total
brown adipose tissue depot in man as Lean et. al. (1986) have suggested that
other sites may be important sources of adipocytes containing uncoupling
protein? If the response of rats is to be extrapolated to man then the 1%
contribution of perirenal tissue means this site represents only one fiftieth
of the total brown fat deposit in man. This would result in the assumption of
a brown adipose tissue depot in excess of 1 kg expressing maximal
thermogenic activity and therefore containing a significant proportion of
'dark' tissue. Post mortem evidence from the present study, and those of
Astrup et. al. (1985b) and Heaton (1972) does not support the presence of
brown adipose tissue depot in man of these proportions.
If the noradrenaline stimulated increase in whole body oxygen
consumption is not derived from brown adipose tissue in the human adult
which tissue or tissues are then responsible for this use in metabolic rate?
In the study referred to above in which perirenal brown adipose tissue
thermogenesis following oral ephedrine was measured (Astrup et. al. 1985b),
oxygen consumption and blood flow was simultaneously measured in leg
skeletal muscle. The increase in leg skeletal muscle oxygen consumption was
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estimated to be 68.2 ym O^/min/lOO ml and assuming 50% of total, body
weight is skeletal muscle, the contribution of this tissue can be calculated to
be 20-30 ml/min - compared to the whole body peak increase in response to
ephedrine of 50 ml/min. Thus following ephedrine administration 50% the
response can be accounted for by skeletal muscle thermogenesis.
The mechanisms contributing to this thermogenic response in muscle
remain to be determined but may be related to blood flow (Mejsnar and
Pacha, 1983) and catecholamine effects on calcium (Rasmussen and Clausen,
1982) and sodium pumping (Kjeldsen et. al., 1984) and protein synthesis
(Emery et. al., 1984).
In conclusion although the present studies have confirmed and
demonstrated the presence of functional brown adipose tissue in adult man
with some potential for thermogenesis, the respiratory inadequacy of human
brown fat suggests that considerable caution must be exercised in
extrapolating the results of animal studies to the human. Based on this
evidence, the reported thermogenic defects in Type I diabetic (Leslie et. al.,
1986; Section 3.3.6), obese (dung et. al., 1979) and lactating subjects
(Illingworth et. al., 1986) are unlikely to be the result of defective brown






In this final chapter I will attempt to draw together the various
strands of the arguments presented in this thesis to formulate how the
present work has contributed to the current concepts of the control of
energy balance and, in the light of this discussion, what direction future
studies should follow.
The starting point of any discussion on the control of energy balance
is the law of mass action which, in this context, states that the maintenance
of a stable body weight is the result of the balanced equation shown below:
ENERGY INPUT ► ENERGY EXPENDITURE
The balance of this equation can be disturbed in favour of weight gain by
three methods:
i) Hyperphagia ► | Energy Input^ Y Energy Expenditure
(constant)
I
•0 Energy Input ^Energy Expenditure '
(constant) *
or a combination of the above
-tiii) Hyperphagia—► | Energy Input Y Energy Expenditure
The present work has not formally addressed the difficult problem of
assessing the contribution of hyperphagia to energy balance but the
experiments in which energy expenditure was measured before and during
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fat supplementation (Section 3.3.3.2) do demonstrate that in the short term
caloric excess does not result in a measurable compensatory increase in
energy expenditure.
Evidence in favour of the hypothesis shown in equation (ii) was
presented in the experiments where the fall in RMR in Type 1 diabetic
subjects with improvement in glycaemic control was associated with an
increase in weight (Section 3.3.2). This does not necessarily infer a causal
effect as the contribution of energy intake over that period was largely
uncontrolled but does for the first time demonstrate an association between
an alteration in energy expenditure and body weight.
I have demonstrated abnormal noradrenergic thermogenesis in Type I
daibetes which appears to be independent of the degree of glycaemic control
(Section 3.3.6). Type II diabetic subjects with similar levels of glycaemic
control to those Type I diabetic subjects on CSII had normal thermic
responses to noradrenaline (Section 4.3.6). Further, Illingworth et. al. (1986)
have also demonstrated blunted thermic responses to noradrenaline in
non-diabetic lactating subjects. These data can be interpreted as failing to
support the hypothesis, extrapolated from animal models (Rothwell and
Stock, 1981) that insulin is a major factor in determining sympathetic
induced thermogenesis in man.
The conflicting data on noradrenergic responsiveness in obesity
(Section 3.4.4) may be reconciled with recent data from Connacher et. al.
(1987, in press) who examined the thermic responses to noradrenaline
infusion in a large group of subjects (40 obese; 19 lean) and demonstrated
that although a blunted thermic response to noradrenaline was more
commonly associated with obesity than leanness, only 26% of obese subjects
demonstrated a significantly blunted response. In the light of this data it
may be more correct to interpret a diminished thermic response to
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noradrenaline in terms of a "marker" or "risk factor" rather than an
aetiological prerequisite to the obese state.
One can make an analogy with another common disorder, hypertension,
which similarly has an incompletely understood aetiology. A minority of
hypertensive subjects may have an identifiable cause such as a renal or
endocrinological disorder but the vast majority are of multifactorial origin
with genetic factors, cigarette smoking, obesity and abnormal vascular
reactivity all independently contributing to the expression of the hyper¬
tensive state (Semple and Lever, 1986). This lack of understanding of the
basic pathophysiology has however not resulted in therapeutic nihilism but
has stimulated attempts to manipulate vascular tone (diuretics, beta blockers
and calcium antagonists) and the hormonal milieu (angiotensin converting
enzyme inhibitors) which although not proven to have an aetiological role
nevertheless provide a means of altering the hypertensive state.
Similarly with obesity - although an abnormality of energy expenditure
may not be involved aetiologically in the majority of cases, dietary
manipulation and treatment with thermogenic agents may nevertheless
provide us with a method of tackling this major problem. Ephedrine (Astrup
et. al., 1985a) and more recently the new generation of 8-agonists (Zed et.
al., 1985) have been shown to facilitate weight loss in obese subjects and
although the present work demonstrates that these are unlikely to be acting
via perirenal brown adipose tissue, as the results of animal models would
have led to speculate, nevertheless they may represent an important advance
in the clinical management of the obese subject.
How then are these drugs acting and how may we study them?
Substrate cycling (Section 1.3.1) is a much discussed method of achieving the
dissipation of excess calories through futile interconversion of carbohydrate,
fat or protein moieties. As discussed earlier the triglyceride-fatty acid cycle
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has been studied in human adipose tissue (Hammond and Johnston, 1987, in
press) and would appear to be energetically insignificant, thus focussing
attention on muscle (Astrup et. al. (1985b) and liver (Berry et. al., 1985). The
contribution of these metabolic masses to daily energy expenditure has to
date only been crudely assessed when the RMR is expressed in terms of lean
body mass in lean and obese subjects. However, results to date (Pittet et. al.,
1976; Ravussin et. al., 1983) demonstrate that obese subjects do not appear
to have a significantly lower RMR per kg lean body mass. With the
increasing sophistication of in vitro techniques for studying the fate of
radiolabeled substrates in human hepatocytes and skeletal muscle
preparations and the advent of newer technology such as nuclear magnetic
resonance which may permit the study of these processes in vivo and enable
the contribution of substrate cycling to energy expenditure to be
reexamined. Further, the study of the control of these processes may provide
us with a new generation of pharmacological agents capable of accelerating
energetically wasteful reactions with potential anti-obesity applications.
To conclude, the term, obesity, is simply a clinically useful description
of those subjects who are greater than 120% ideal body weight. It is however,
not a distinctly defined syndrome but probably represents the sum of a
heterogeneous group of disorders which themselves may be multifactorial in
origin. The spectrum of abnormalities predisposing an individual to obesity
may range from simple gluttony to multiple, and as yet largely undefined,
abnormalities of energy expenditure, energy intake and neuro¬
endocrinological disorders. The key lies in defining these various clinical
entities more precisely.
The present studies have attempted to define more clearly the
contribution of two factors in the control of energy balance, namely those of
insulin and brown adipose tissue in man, and have demonstrated the
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complexity and difficulties that may be encountered in extrapolating from
animal models to adult man.
Ultimately, our understanding of the pathological disorders of under-
and overnutrition will develop from a greater knowledge of the homeostatic
mechanisms that have, for example, maintained my own body weight at 69.5
± 1 kg during the three year period that this work has been performed.
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Epilogue
"Man is not a rat"
- Attributed to T.H. Huxley (1825-1895)
"The proper study of mankind is man"
- Alexander Pope (1773)
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10920 IF V$="H" THEN 11000
10930 2=0 : G0T0 10140
11000 RETURN
11215 OPENS,.4 sCMD5
11220 PRINT" , r -!■ t- , i
11230 PRINT" iTIME | 002 j 02 I I H, P. j
11240 PRINT" | MINI PROD. | CONS. ] R.Q. | KJ/MIN I
11250 PRINT " I 1 \ 1 1 1" sRETURN
12000 N0= I NT C < FIBS < N > 1 /M > ,-'4 > :P$=S TRT CN0 > :: P$=R IGHTT < P$ , L..EN C PT > -1 >
12010 I FP= 1 THENPR I NT " .2
12020 IFN C0THENPRI NTSP.C C 13 > " - „ 00 " P$ :: RETURN
12030 PR INTSPC C 13 " . 00 " PT s RETURN
12900 PR I NT " SPC 1S > " THE END " s GOTO 13000
13000 FOR I = 1TOL. sNENT s PR I NT " □" .? : END




14040 PR I NT" aiil^MSUBJECT THEREFORE NEEDS " .jV; "ML OF RECONSTITUTED BUILD-UP"
14050 PRlNT"SWi|I'1AKE UP 0.5MG NORADRENAL INE WITH 50ML OF SALINE"
14060 PRINT";g|i|»HspUMP SHOULD BE SET AT " .sR.? "ML/HR FOR THIS SUBJECT
14070 END ,
15000 REM SUBROUTINE TO PRINT OUT RESULTS
15010 0PEN 54 2 G0T0 6529
15020 CMD5 s G0SUB11220
15025 PRINT#5sCLOSES
.1.5030 UPEN 6 ,• 4 .2
15035 OPEN 7 ,•41
15040 F'R I NT#6" 999 ' .999- .999- 9.999- 9.999 "
15050 FOR 1 = 1 TO R :F=I*D+4::





200E10 REM SAP El V S I UkHGl-
20010 PRINT"□ SAFETY STORAGE IN PROGRESS
20020- NPT=MAT+"/S"
20025 B=B+2
20030 D C 0 > =B
22430 OOPEN#2 , C NPT > D1W
22431 IF DSO0 THEN PR INTDST ; STOP
22432 FOR 1=8 TO B s F'R INT#2.. D C I
22433 IF DSO0 THEN PRINT DSTsSTOF"
22434 NEXT sVVt=CHRT C13>
22435 PR INT#2NAT .2 V'r'T .2 DT .2 VVT .2 TT ,2W$ .2Hi s VVT .2 VT .2 VVT .2 WT
22436 IF DSO0 THEN PRINT DST sSTOP
22448 CLOSE2 2 PR I NT " SIDATA STORED
23000 RETURN
READY.
